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Abstract: Among the several delivery materials available so far, polysaccharides represent 
very attractive molecules as they can undergo a wide range of chemical modifications, are 
biocompatible, biodegradable, and have low immunogenic properties. Thus, polysaccharides 
can contribute to significantly overcome the limitation in the use of many types of drugs, 
including anti-cancer drugs. The use of conventional anti-cancer drugs is hampered by their 
high toxicity, mostly depending on the indiscriminate targeting of both cancer and normal 
cells. Additionally, for nucleic acid based drugs (NABDs), an emerging class of drugs with 
potential anti-cancer value, the practical use is problematic. This mostly depends on their 
fast degradation in biological fluids and the difficulties to cross cell membranes. Thus, for 
both classes of drugs, the development of optimal delivery materials is crucial. Here we 
discuss the possibility of using different kinds of polysaccharides, such as chitosan, 
hyaluronic acid, dextran, and pullulan, as smart drug delivery materials. We first describe 
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the main features of polysaccharides, then a general overview about the aspects ruling drug 
release mechanisms and the pharmacokinetic are reported. Finally, notable examples of 
polysaccharide-based delivery of conventional anti-cancer drugs and NABDs are reported. 
Whereas additional research is required, the promising results obtained so far, fully justify 
further efforts, both in terms of economic support and investigations in the field of 
polysaccharides as drug delivery materials. 
Keywords: polysaccharides; anticancer drugs; NABDs; delivery 
 
1. Introduction 
Polysaccharides can be defined as polymeric carbohydrate structures composed of repeating 
monosaccharide units joined by glycosidic bonds [1]. These natural polymers are, by far, the most 
abundant renewable resource on the Earth, with an annual formation rate exceeding the world production 
rate of synthetic polymers by some orders of magnitude. Interestingly, naturally designed polysaccharides 
can carry out various different functions. For example, they can accomplish structural tasks, such as 
cellulose and chitin, storage functions, such as starch and glycogen, and gel structures (made up of mono- 
and copolymers), such as mucopolysaccharides (glycosaminoglycans), agar, and pectins [2]. 
Polysaccharides found and continue to find wide application in the drug delivery field [3–8] for 
various and important reasons: (1) they can be obtained in a well characterized and reproducible way 
from natural sources [9]; (2) they can undergo a wide range of chemical and enzymatic reactions to give 
origin to different materials [10]; (3) they are biocompatible, biodegradable and have low immunogenic 
properties [11]; (4) ionic polysaccharides can, partially, or even totally, substitute synthetic polymers in 
the design of stimuli responsive drug delivery systems since they show pH- and ion-sensitiveness [12]; 
(5) ionic polysaccharides are muco-adhesive [13]; (6) they can be prepared as conjugates or complexes 
with proteins, peptides, and other bio-macromolecules [14]; (7) they can easily form gels [14]; and  
(8) they can give rise to interpenetrated polymeric networks (IPN) and semi-IPN that can show  
physico-chemical properties which are remarkably different from those of the macromolecular 
constituents [15]. All these characteristics make polysaccharides excellent materials for the realization 
of “smart” delivery systems capable to release, at the appropriate time and site of action, entrapped drugs 
in response to specific physiological stimuli [15]. 
The aim of this review is to present relevant polysaccharides and to show some of their most 
significant applications in the drug delivery fields. More in detail, in Section 2 we will provide a general 
overview of polysaccharides structure, types, and delivery/absorption mechanisms; in Section 3 and 4 
we report examples of the use of polysaccharides as delivery materials for clinically used anticancer drugs 
and experimental nucleic acid based drugs (NABDs), chosen as relevant examples among existing drugs. 
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2. Polysaccharides 
2.1. Polysaccharide Structure 
Polysaccharide classification basically relies on their “primary or covalent structure” that represents 
the sequence of monomeric units along the chain [2,10]. These units are, usually, characterized by a 
heterocyclic structure, where one atom is oxygen and the remaining are carbon atoms. The most common 
repeating units, which naturally occur in the polysaccharide chains, present a six-membered ring 
structure. Despite the carbon atom numbers, the monomeric units are linked by chemical bonds of 
covalent nature that connect the carbon atom in position 1 (C(1)) through an oxygen bridge to a carbon 
atom of the following unit via the so-called “glycosidic linkages” (Figure 1). 
As these covalent linkages are not completely flexible (they limit the monomers to a narrow range of 
relative orientations), an isolated polysaccharide chain can only adopt certain shapes (called “secondary 
structures”), which are dependent on their primary sequence. At a higher degree of organization, 
energetically favorable interactions between shaped chains may result in ordered specific structures 
known as “tertiary structures”. Finally, such compact entities may interact among themselves to give 
higher levels of organization, which are described as “quaternary structures”. Common examples of 
polysaccharide “secondary structures” (called conformations) are ribbons and helices. “Tertiary structures” 
are represented by the arrangement of multiple helices or aggregates of ribbons, as shown in Figure 2, 
in the case of cellulose and starch. 
 
Figure 1. Glycosidic linkage between two different saccharide units. Schematic 
representation of cellobiose (top) and maltose (bottom). In the first case, the anomeric 
carbon (C2) is in the beta configuration (equatorial), while in the second case, it is in the 
alpha configuration (axial). 
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Figure 2. Schematic representation of ribbons and a ribbon aggregate (left), as found in 
cellulose, and of a helix (right), as found in starch. Hydrogen bonds are represented by 
dashed red lines. 
2.2. Polysaccharides Types 
As shown in Table 1, polysaccharides can have animal, vegetal (algae, plants, seeds, and exudates), 
and microbial/fungi origins.  
Therefore, they hold a wide range of different functions. Polysaccharides can act as energy storage 
materials, such as starch, glycogen, and polysaccharides of some plant seed (locust bean gum and guar gum). 
Polysaccharides can also contribute to the structural integrity and mechanical strength of plant tissues 
by forming a hydrated cross-linked three-dimensional network, as in the case of pectins in land plants 
and carrageenans, agar, and alginate in marine species. In the animal world, hyaluronate, chondroitin 
sulfate and other related glycosaminoglycans play a fundamental part in governing the solution 
properties of some physiological fluids and in the structure of the intercellular matrix. Polysaccharides 
may also work as protective substances, as in the case of exudate gums from plants, where they provide 
a preventive function by sealing off the injured parts of the plant against bacterial infections. 
Table 1. Origin of Polysaccharides. 
Animal Polysaccharides 
Chitin 
Chitosan [16–28] 
Glycosamminoglycans [29–38] 
Vegetal Polysaccharides 
Land Vegetal Marine Vegetal 
Cellulose [39–41] Alginate (Phaeophyceae—brown seaweed) 
Pectins Agar (Rhodophyceae—red seaweed) 
Galactomannans Carragenans (Rhodophyceae—red seaweed) 
Acacia gum – 
Starch – 
Microorganisms/Fungi 
Alginate (Pseudomonas aeruginosa and Azotobacter vinelandii) [42–44] 
Dextran (Leuconostoc spp. and Lactobacillus spp.) [45–50] 
Gellan (Pseudomonas elodea) 
Pullulan (Aureobasidium pullulans) [51–53] 
Scleroglucan (Sclerotium glucanicum) Xanthomonas campestris 
Xanthan (Xanthomonas campestris) 
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2.2.1. Animal Polysaccharides 
Chitin, a high molecular weight polysaccharide, is a fundamental skeletal material in crustaceans, 
insects, and spiders that contributes to the structure of the exoskeleton, the lining of the gut, the tendons, 
the wing coverings, and the internal skeleton. The primary structure of chitin is closely related to that of 
cellulose (linear polymer of 1,4-linked β-D-glucopyranose), except for the replacement of the –OH group 
at each C(2) position by an acetamido group –NHCOCH3. Chitosan is the name given to fully or partially 
deacetylated chitin. 
Glycosaminoglycans (GAGs) are polysaccharides that contain amino sugars and are constituents of 
the extracellular space of many mammalian tissues. With the exception of hyaluronic acid, they are 
covalently linked to proteins in the natural state, and in this form, they are known as proteoglycans. 
Hyaluronic acid is a basic component of the extracellular matrix of connective tissue and it is present in 
large amounts in the vitreous humour of the eye, the synovial fluid of the joints, and in soft tissues,  
such as umbilical cord and rooster comb. In addition, hyaluronic acid has many peculiar  
chemical–physical and biological properties, which enable it to regulate and control the physiological 
functions of several tissues in vivo. In virtue of its extraordinary water-retaining capability, in aqueous 
solutions hyaluronic acid shows a high excluded volume since it behaves as an expanded random coil 
occupying large hydrodynamic volume. This is the reason why it is generally affirmed that it controls 
and regulates the trafficking of fluids and macromolecules within the interstitial space of tissues [54]. 
2.2.2. Vegetal Polysaccharides 
Cellulose, a high molecular weight (≈7 × 105–3.2 × 106 [10]) linear polymer of 1,4-linked  
β-D-glucopyranose, can be defined as the backbone of the vegetal kingdom as it is one of the most 
abundant and important component of land-growing plants. 
Pectins represent a group of polysaccharides that occur as structural materials in all land-growing 
plants. They belong to the interrupted chain sequences family, being characterized by linear 1,4-linked 
α-D-galactopyranosyluronic acid sequences separated by α-L-rhamnopyranosyl residues. Galactomannans 
represent a class of polysaccharides that can be found in plant seeds such as carob or locust bean, guar, 
tara, and tamarind. These polysaccharides, or gums as they are often called, are derived from the 
endosperm of various leguminosae plant seeds, where they function as reserve materials utilized during 
germination. Most of these carbohydrate polymers share basic structural similarities consisting of linear 
1,4-linked chains of β-D-mannopyranosyl residues to which single α-D-galactopyranosyl side chains are 
linked at position 6. Depending on the seed source, galactomannans can differ in their molecular weight, 
molecular weight distribution and galactose to mannose composition ratio (G/M). Moreover, at a given 
G/M ratio, they can also differ in terms of the side chain distribution along the mannan backbone.  
Gum Arabic, or acacia gum, is the most famous natural exudate, produced by more than 900 species of 
the Acacia trees. Natural Arabic gum is a mixture of potassium, magnesium and calcium salt of  
an acidic polysaccharide composed of six different carbohydrate units: D-galactopyranose,  
D-arabinopyranose, L-arabinofuranose, L-rhamnopyranose, D-glucopyranosyluronic acid and 4-O-methyl-D-
glucopyranosyluronic acid. 
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A common function of polysaccharides that preferentially adopt hollow helix conformations is to act 
as energy reserves in biological systems. For these biopolymers, the conformations are relevant to their 
biological functions as they allow the macromolecules to be piled together and accumulated as 
concentrated deposits. These deposits can be organized in such a way that osmotic transport phenomena 
within the tissues are not affected and, yet, the molecules within them are easily accessible to be 
mobilized and employed when necessary. A typical example of energy reserve polysaccharide is 
represented by starch that, in nature, occurs as minute granules (2–100 μm particle size) in the roots, 
seeds, and stems of numerous types of plants including corn, wheat, rice, millet, barley, and potatoes. 
Starch is made up of a linear polymer, called amylose (1,4-linked α-D-glucopyranose units), and a 
branched polymer called amylopectin (linear backbone of 1,4-linked α-D-glucopyranose monomers 
bearing clusters of 1,6-α-linked glucopyranosyl branches with average length of 20–30 residues). 
Amylose constitutes only the 25% by weight of the total starch. 
Polysaccharides can be also found in marine seaweeds or algae. Their task is similar to that of 
cellulose in land plants, with the difference that seaweeds need a more flexible structure to support the 
varying stresses due to currents and waves. The many varieties of seaweeds are usually subdivided on 
the basis of their predominant color pigments. Accordingly, Cyanophyceae (blue-green), Xanthophyceae 
(yellow-green), Chlorophyceae (green), Rhodophyceae (red), and Phaeophyceae (brown) can be 
mentioned. Among the many polysaccharides present in seaweeds and algae (see Table 1), from the  
drug delivery point of view, the most important are alginates and agar. The term alginate refers to  
a family of unbranched polysaccharides isolated from brown seaweeds [55]. They are composed of  
1-4-linked β-D-mannuronic acid (M) and alpha-L-guluronic acid (G) arranged in a block-wise pattern 
with homopolymeric regions of M-blocks and G-blocks residues interspersed by regions of alternating 
structures (MG-blocks). The polysaccharide, known since 1881, has largely been used in 
biotechnological and industrial applications for its gel forming properties, which were described in detail 
around the 1970s by Grant [56] and Smidsrød [57]. 
The general term agar refers to a complex mixture of polysaccharide components which can be 
extracted from certain species of red seaweeds. Agar is composed of two major fractions: agarose,  
a neutral polysaccharide, and agaropectin, a charged, sulfated carbohydrate polymer. The percentage of 
agarose normally ranges from 50% to 90% of the total agar. The linear agarose backbone is based on a 
disaccharide repeating unit of the AB type, consisting of alternating 1,3-linked β-D-galactose (A) and 
1,4-linked 3,6-anhydro-α-L-galactose (B). Depending on the algal sources, 6-O-methyl-D-galactose  
may also be present in variable amounts (1%–20%). Interestingly, agarose can give origin to  
thermo-reversible hydrogels. 
Carrageenans are sulfated linear polysaccharides which can be extracted as matrix components of red 
seaweeds. Their chemical structure is based on a disaccharide repeating unit of the AB type so that they 
can be written generally as (AB)n, where A is derived from a 1,3-linked β-D-galactose unit and B is 
usually, but not always, present as 1,4-linked 3,6-anhydro-β-D-galactose. Carrageenans sulfation takes 
place at position 2 and 4 in 1,3-linked galactose residues, whereas the 1,4-linked units occur as  
2-sulfate, 6-sulfate, 2,6-disulfate and 3,6-anhydride-2-sulfate. No sulfation at C(3) apparently occurs. 
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2.2.3. Microorganisms/Fungi Polysaccharides  
Microorganisms, such as bacteria and fungi, produce three distinct types of polysaccharides:  
(1) extracellular or exo-cellular polysaccharides, which can be found in the form of a discrete capsule 
that envelops the microbial cell and that is part of the cell wall itself (capsular polysaccharides),  
or as an amorphous mass secreted into the surrounding medium; (2) structural polysaccharides; and  
(3) intracellular storage polysaccharides.  
The bacterial alginate is exo-cellularly produced (partially acetylated) by the bacteria  
Pseudomonas aeruginosa and Azotobacter vinelandii and its physical and chemical properties are very 
similar to their algal counterparts. O-acetylation invariably seems to be a characteristic feature in 
bacterial alginates that distinguishes them from the seaweed alginates. 
Dextrans constitute a family of microbial polysaccharides produced by Leuconostoc spp. and 
Lactobacillus spp. Dextran is almost exclusively composed of 1,6-linked α-D-glucopyranose units with 
varying proportions of other bond types, such as α-1,3, α-1,2 and α-1,6 branch linkages. Gellan gum is 
produced by the bacterium Pseudomonas elodea and is composed of D-glucose, D-glucuronic acid and 
L-rhamnose in a molar ratio of 2:1:1. The primary structure of gellan is based on the tetra-saccharide 
repeating unit. Both O-acetyl and O-L-glyceryl substituents are present along the main chain,  
the former at the C(6) position and the latter at the C(2) position of the 3-linked glucose unit. The  
exo-cellular Pullulan, produced by the yeast-like fungus Aureobasidium pullulans, is a linear polymer 
composed of glucose residues polymerized into repeating malto-triose units. The malto-triose units are  
linked via α-1,6 bonds; within each unit the glucose residues are linked α-1,4. Nevertheless, some  
1,6-α-D-maltotetraose repeating units and 1,3-linked glucose residues have also been found as 
components of pullulan primary structure. The molecular weight of this polysaccharide can vary in the 
range 1.5 × 103–4 × 106 depending on the culture conditions and strain of microorganisms used.  
Scleroglucan, a neutral capsular polysaccharide, is exo-cellularly secreted by certain imperfect  
fungi, particularly of the genus Sclerotium. The primary structure of scleroglucan from  
Sclerotium glucanicum has been characterized as a linear chain of β-1,3-linked D-glucose units with 
single D-glucose side chains linked β-1,6 to every third unit of the main chain. Scleroglucan molecular 
weight varies in the range 3.2 × 105–1 × 106. Xanthan gum is an anionic polymer secreted  
exo-cellularly by the bacterium Xanthomonas campestris. Its primary structure is based on a linear 
backbone of 1,4-linked β-D-glucose. At the C(3) position of every alternate glucose residue there is a 
charged tri-saccharide side chain containing a glucuronic acid residue between two mannose units.  
The terminal β-D-mannose is linked β-1,4 to the glucuronic acid, which, in turn, is linked α-1,2 to the  
α-D-mannose. In approximately one half of the terminal mannose residues, a pyruvic acid moiety is joined 
by a ketal linkage to the O(4) and O(6) positions. Acetyl groups are present as substituents at the O(6) 
position of the nonterminal D-mannose.  
2.3. Polysaccharide Gels  
Undoubtedly, among the different interesting properties of polysaccharides, the possibility of forming 
gel structures is, from the drug delivery point of view, very interesting. Indeed, gels, defined as coherent 
systems made up of a three-dimensional polymeric network trapping a continuous liquid phase  
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(water or physiological media in the case of hydrogels) [10] (see Figure 3), can efficiently and reliably 
control the drug release kinetics of embedded drugs [58]. The presence of inter-chains linkages, called 
crosslinks, prevents the solubilization of the network of the polymeric chains in the fluid phase. 
Interestingly, despite the very large amount of liquid phase that can be hosted inside the polymeric 
network (the polymeric network volume fraction in the gel can be lower than 1%), gels show mechanical 
properties in between those of solids and liquids [10], thus, mimicking living tissues very well [59]. 
 
Figure 3. TEM image referring to a hydrogel obtained via the crosslinking of an alginate 
water solution (alginate mass fraction 2%) by means of a Ca++ solution (5 g/L). Alginate 
chains are represented by the dark wires while water occupies the gray zones. Details about 
the hydrogel treatment for the TEM analysis are reported in [60]. 
The chemical–physical properties of the polymeric network chains and the huge amount of absorbed 
water, make polysaccharide gels attractive candidates also for the release of proteins, peptides, vaccines 
and NABDs that can be embodied into the three-dimensional polymeric network meshes. The use of 
polysaccharide as delivery systems is also strengthened by the fact that hydrogel realization implies the 
use of safe procedures that do not imply proteins/NABDs denaturation. Thus, controlled release systems, 
based on polysaccharides hydrogels, can be a reliable tool to ensure the therapeutic 
proteins/peptides/NABDs concentration in tissues or in the blood for a long time [14]. 
Based on the crosslinked nature, (polysaccharides) hydrogels can be defined as chemical or physical. 
In the first case, crosslinks between different chains are strong, permanent, and punctual as they are due 
to covalent bonds. Conversely, in the second case, crosslinks are due to either polymer chains topological 
entanglements (spaghetti-like configuration, Figure 4) or physical interactions (this being typical of 
glucans and xanthan), such as H-bonds, ionic, Coulombic, van der Waals, dipole–dipole, and 
hydrophobic interactions. 
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Figure 4. Structures occurring in physically cross-linked polysaccharides gels. 
As a consequence, crosslinks are not punctual but they form junction zones where the regular coupling 
of chain portions belonging to different polymeric chains takes place. It is interesting to observe that the 
long chain segments departing from the ordered junction zones can form, with other chains, additional 
junction zones to form a polymeric three-dimensional network. As, in general, the physical interactions 
occurring in junction zones are not so strong, these junctions are often transient. Thus, they give origin 
to a statistical network characterized by a constant average crosslink density (moles of crosslinks per gel 
unit volume) and a time dependent distribution of crosslinks. These means that, due to Brownian motion 
of chains and segment of chains, network meshes continuously appear and disappear, being the average 
mesh number and dimension constant [10,58]. Figure 4 shows some typical situations occurring in the 
formation of polysaccharide gels.  
Basically, drug delivery from hydrogels as those formed by polysaccharides, is ruled by physical 
processes, physicochemical processes, and system parameters [61]. In particular: (1) physical processes 
can include matrix swelling and erosion; (2) physicochemical processes can include matrix erosion, drug 
dissolution (recrystallization), drug transport (by diffusion and convection), drug interaction with 
hydrogel polymeric chains; and (3) system parameters can be represented by initial drug distribution and 
concentration inside the hydrogel, hydrogel geometry (cylindrical, spherical, etc.), and hydrogels size 
distribution (in the case of an ensemble of hydrogel particles). Of course, among all the above mentioned 
phenomena, those strongly affected by the hydrogel network topology are swelling, erosion, and drug 
diffusion. On the contrary, network physicochemical characteristics can play an important role for what 
concerns the drug interaction with the polymeric chains. In general, if the network topology highly 
affects the drug release kinetics from hydrogels ranging in the milli- or micro-range, polymer–drug 
interaction becomes the most important aspect for polymeric nano-delivery systems. 
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2.4. Polysaccharide Micro and Nanoparticles 
Whereas polysaccharides can be used in the form of gel to deliver therapeutic drugs, they can be also 
arranged in the micro-nanoparticle shape. This last use has been limited in the past due to the harsh 
conditions necessary to prepare the particles, a fact that may compromise drug stability and loading 
efficiencies [62,63]. A recently developed approach to overcome this limitation is represented by the 
generation of super-hydrophobic surfaces [62]. This method is based on the preparation of a water 
solution containing the monomer (or polymer) and the drug at the desired concentration. Then, the 
aqueous solution is put on a super-hydrophobic surface constituted, for example, by surface modified 
copper, aluminum, or polystyrene substrates. Due to the high hydrophobicity of these surfaces, the 
aqueous solution assumes an almost perfect spherical shape whose diameter essentially depends on the 
solution volume deposited on the surface. The subsequent exposure to the polymerisation/crosslinking 
process leads to the formation of spherical particles [63]. Since the process takes place at the solid–air 
interface, no migration of the drug occurs, and, thus, 100% loading yield is possible [62]. Relying on this 
approach, Lima and co-workers [63] were able to realize spherical hydrogel particles, made up by 
interpenetrated dextran-methacrylated and poly(N-isopropylacrylamide) polymers, for the release of 
insulin and bovine serum albumin. Interestingly, they proved that the release kinetics could be tuned 
acting on particles composition and release environment temperature. 
Whatever the technique used to prepare the drug loaded particles, the in vivo fate of the particles 
depends on some common steps reassumed by the ADME processes, i.e., Absorption, Distribution, 
Metabolism and Elimination [64]. In the case of particulate delivery systems, such as those based on 
polysaccharide particles, cell membrane crossing (absorption) represent a critical step. In particular,  
the net superficial charge of the particles plays a key role. Whereas anionic complexes usually show 
good solubility and, thus, stability in the physiological environment, they cannot efficiently cross cell 
membranes. This is due to the electrostatic repulsion occurring with the negative electric charge of the 
cell membranes. Conversely, cationic complexes can efficiently bind to cell membrane due to the strong 
electrostatic interactions. Unfortunately, however, if the interaction is too strong, it can cause membrane 
disruption and consequent cell death. In addition, the presence of negatively charged blood proteins can 
induce the formation of complex-protein aggregates that are no longer soluble and precipitate. Whereas 
neutral complexes are not affected by the above mentioned problems, in the physiological environment 
they tend to associate each other resulting in a limited solubility. Thus the charge of the particles has to 
be carefully selected. Ideally the particle charge should guarantee a good stability in the physiological 
environment and should be able to allow an efficient interaction with the cell membrane without inducing 
significant damages. 
Although very important, the surface properties are not the only variables affecting the in vivo 
particle/drug fate. In particular, the particle dimension and shape can affect the transport through 
biological barriers (e.g., microvascular walls, interstitial space, and cell membranes) [65]. It is well 
known that, in general, small nanoparticles (≤100 nm) are efficiently internalized by cells, while bigger 
particles are not [66]. However, nanoparticles suffer for the lack of the so called “margination effect” 
which consists in the movement of particles in flow toward the walls of a channel (blood vessel) [67]. 
Essentially, nanoparticles move inside the vessel (together with red blood cells) with a uniform radial 
distribution and limited near-wall accumulation. On the contrary micro-particles tend to preferentially 
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accumulate next to the vessel walls, in a particle size and shape-dependent manner [65,67].  
This localization facilitates micro-particle extravasation, thus favoring drug delivery to the surrounding 
tissue. In contrast, nanoparticles, which have a limited near-wall accumulation, have more difficulties to 
extravasate and thus to deliver the drug to the tissues. The margination phenomenon is particularly 
relevant in vessels nourishing tumor tissues due to their leaky nature (enhanced permeability and 
retention effect) which favors extravasation [67]. Thus, the extravasation of particles localized near the 
vessel wall (microparticles) is facilitated; in contrast, the extravasation of particles localized far from the 
vessel wall (nanoparticles) is disfavored.  
3. Polysaccharide-Based Delivery Systems for Anti-Cancer Drugs  
Most, if not all, the concepts expressed in Sections 2.3 and 2.4, with regard to the variables ruling 
drug delivery from polysaccharides, hold true for any drug delivery approach. This implies that the works 
reported in the next sections are the result of the complex interplay among all the aspects ruling drug 
release either from polysaccharide gels or particles. To make the text easily understandable, these aspects 
are generally omitted in the description of the experimental works; the focus is in contrast put on some 
other features peculiar of the specific polysaccharide-based delivery system.  
The presented works have been subdivided into two parts: the first (Section 3.1) describing examples 
of the release of clinically relevant anticancer drugs, and the second (Section 3.2) describing examples 
of the release of nucleic acid based drug.  
3.1. Polysaccharides for the Delivery of Clinically Relevant Anti-Cancer Drugs  
In addition to the drug delivery aspects reported in Sections 2.3 and 2.4, other features specific to the 
delivery of clinically relevant anti-cancer drugs, have to be highlighted. We believe this is important to 
better understanding the rationale of the polysaccharide-based delivery examples described. For this 
purpose, in Sections 3.1.1 and 3.1.2 are reported some important aspects of drug delivery together with 
the main features of commonly used drugs, respectively. These two sections are then followed by the 
description of different polysaccharide-based delivery systems (Sections 3.1.3–3.1.8). 
3.1.1. Critical Aspects of Systemic Drug Administration 
The critical bottleneck of the administration of conventional cancer therapeutic molecules is 
represented by their high toxicity [68,69], mostly dependent on the indiscriminate distribution between 
diseased and healthy cells. Toxicity may also depend on the presence, in the pharmaceutical preparations, 
of organic solvents/detergents necessary to improve the poor solubility in water of many of these  
drugs [70]. Therefore, the development of targeted drug delivery systems with switchable (generally  
pH-dependent) drug release profiles has become a relevant issue in chemotherapy [71].  
The conjugation of chemotherapy agents to macromolecules may offer several advantages (Figure 5).  
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Figure 5. Advantages of chemotherapy agent conjugation with macromolecules. 
Macromolecules can ameliorate drugs’ pharmacokinetics (PK) and pharmacodynamics (PD) by 
different phenomena. Regarding PD, macromolecules have high drug loading capacity and, in addition, 
can be equipped with targeting molecules to increase drug specificity. In some cases, stimuli-responsive 
delivery has been studied to improve drug release in cancer tissues. In this regard, for example,  
pH-sensitive drug delivery systems take advantage of the different pH in normal (pH~7.4) vs. cancer 
(pH < 6) tissue [72]. With regard to PK, macromolecules can increase blood circulation time, reduce the 
volume of distribution and prolong the distribution/elimination phases [73]. It is also noteworthy that,  
in general, polymer–drug conjugates are not able to cross the endothelium surrounding healthy vessels. 
This mostly depends on the bigger size of polymer–drug conjugates compared to endothelium 
fenestration. In contrast, in pathological conditions like cancer, local vessels are more permeable due to 
the increased size of endothelium fenestration. Through these gaps, the delivery systems can extravasate 
and reach the tumor where they tend to reside due to the scarce lymphatic drainage. Collectively these 
phenomena go under the name of enhanced permeability and retention (EPR) effect [74]. The use of 
materials able to release the drug slowly, may further improve drug residence at the tumor site, possibly 
ameliorating drug efficacy and reducing side effects. 
The use of macromolecule-based delivery systems also allows facing more complex clinical 
problems. For instance, it is possible to design multidrug delivery systems to improve, on one hand,  
the treatment efficacy and, on the other hand, the compliance of the patients. Another interesting option 
is related to the possibility to design so called “theragnostic” agents, that render possible the 
simultaneous cancer diagnosis and therapy. This approach typically combines the use of a therapeutic 
agent together with a targeting/marker agent, as below detailed. 
Based on the above considerations, chemotherapeutic drugs have been encapsulated, conjugated or 
linked to different carriers [75]. Among these, biopolymers have been frequently used due to their 
biocompatibility, natural occurrence, often targeting ability, relatively inexpensiveness and the possibility 
of derivatization with different chemical groups [76].  
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3.1.2. Anticancer Drugs 
Thus far, a great deal of effort has been spent to design polysaccharide-based systems to deliver  
anti-cancer drugs such as docetaxel (DTX), paclitaxel (PTX), cisplatin (CDDP), 5-fluorouracil (5-FU), 
and doxorubicin (DOX). 
DTX and PTX are mitotic inhibitors belonging to the taxane family. These molecules promote the 
assembly of the free tubulin and stabilize the microtubules, thus, particularly impacting proliferating 
cells. According to FDA guidelines, DTX is indicated for the treatment of various solid tumors such as 
breast cancer, non-small cell lung cancer, hormone refractory prostate cancer, gastric adenocarcinoma, 
squamous cell carcinoma of head and neck. Among the numerous side effects reported, toxic deaths, 
hepatotoxicity, neutropenia, and hypersensitivity reactions can be mentioned. Another important 
limitation of DTX relates to its scarce water solubility that, together with the reported side effects,  
have lead numerous groups to try to ameliorate drug formulation and administration. As DTX, PTX is 
widely used in clinic for the treatment of breast cancer, ovarian cancer, and AIDS-related Kaposi 
sarcoma. The aforementioned side effects depend not only on the drugs, but also on the additives used 
to improve their poor solubility, like the surfactant polysorbate [77,78].  
Another class of drugs commonly used in cancer treatment are DNA damaging agents. Among these, 
CDDP is employed for the therapy of many malignancies including metastatic testicular tumors, 
metastatic ovarian and advanced bladder cancer. Its administration is associated with many side effects 
due to its accumulation in the liver, kidney, and prostate.  
5-FU is an antimetabolite that acts by interfering with the DNA and RNA synthesis. It is prescribed 
for the management of different malignancies such as carcinoma of the colon, rectum, breast, stomach, 
and pancreas. As for other chemotherapeutics, severe hematological and gastrointestinal toxicities and 
even toxic deaths are reported.  
DOX, belonging to the class of anthracyclines, has mainly three different mechanisms of action. First, 
it binds to nucleic acids, intercalating the planar anthracycline nucleus with the DNA double helix; 
second, it interacts with topoisomerase II, an enzyme involved in DNA replication; third, it binds to the 
cellular membrane, affecting a variety of cellular functions. This drug is indicated for different cancers, 
such as bone sarcomas, Hodgkin’s disease, ovary-, breast- and lung-cancer [79]. Among the side effects, 
it can be stressed in particular the cardiotoxicity and the possibility to develop acute myelogenous 
leukemia or myelodysplastic syndrome.  
To improve drug effectiveness but especially to reduce side effects, different delivery options have 
been developed. In the next sections, we will concentrate on those based on the use of polysaccharides 
(Table 2). Most of the examples reported deal with the above-presented anticancer drugs; however, also 
other chemotherapeutics are reported and in these cases, their characteristics are briefly indicated.  
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Table 2. Polysaccharide-based delivery of chemotherapy drugs. 
 System Structure Drug Disease In vitro Model In vivo Model Ref. 
Chitosan 
1 LMWC-PTX LMWC PTX Melanoma, NSCLC – Mouse  [16] 
2 LMWC-DTX LMWC DTX NSCLC, GBM 
NCI-H358, 
U87MG 
Mouse [17] 
3 PTX-Cy5.5-CS NPs PTX SCC SCC7 Mouse [18] 
4 Cy5-CS NPs DOX Sarcoma HT1080 – [19] 
5 
HGCS-Ce6  
GCS-Ce6 
NPs Ce6 
SCC, 
adenocarcinoma 
SCC-7  
HT-29 
Mouse [20] 
6 FLT-CS MPs FLT – – – [21] 
7 
CS/GP  
CS/GP/GE 
Hydrogel CDDP Oral cancer – 
– 
[22] 
Hyaluronic Acid 
8 MSP-HA-DOX Nano-conjugate DOX Breast cancer MDA-MB-231 – [29] 
9 HA-DOX Nano-conjugate DOX Breast cancer MDA-MB-468NL Rat [30] 
10 HA-CDDP Nano-conjugate CDDP Lung cancer A549 Rat [31] 
11 HA-CA-PTX Nano-conjugate PTX 
Head and neck 
cancer  
SCC7, NIH3T3 Mouse  [32] 
12 HACD-AuNPs Gold nanocluster several Breast cancer MCF7, NIH3T3 – [33] 
Dextran 
13 
CMD-g-β-
CD/(PAD-g-
AD&AD-DOX))4 
Microsystem DOX – HeLa  – [45] 
14 DEX-PDP Nanosystem 
DOX, 
CPT11 
Breast cancer  
Colon cancer 
MCF7, DLD1 – [46] 
Pullulan 
15 P-PTX NPs PTX Colon cancer HCT116 Mouse [51] 
Cellulose 
16 HPC-DNR Conjugate DNR – HeLa Mouse [39] 
17 
CMC-PABA, 
CMC-PAH 
Nano-conjugate 
Curcumin 
and 
derivates 
Colon cancer HT29, CRL1790 – [40] 
18 HPC-PAA-CdSe Nanogel TMZ Melanoma B16F10 – [41] 
Other 
19 MR-5-FU NPs 5-FU Breast cancer  MCF7 – [80] 
20 FA-AG-MTX NPs MTX – AA8 – [81] 
3.1.3. Chitosan Based Delivery 
Chitosan (CS) has been considered as delivery material because of its unique physicochemical and 
biological characteristics. The primary hydroxyl and amine groups located on the backbone of CS allow 
chemical modification to control its physical properties. The chemical modifications allow, for example, 
overcoming the low solubility at physiological pH and the poor buffering capacity of CS in its native 
form. Additionally, when a hydrophobic moiety is conjugated to a CS molecule, the resulting amphiphile 
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may form self-assembled nanoparticles (NPs) that can encapsulate a variety of hydrophobic drugs and 
promote proper delivery [71].  
Several examples of drug delivery systems based on CS have been reported in literature. Low molecular 
weight CS (LMWC) (MW < 10 KDa) conjugated with PTX (LMWC-PTX) through a succinate linker, 
was synthesized as a NP carrier for the oral delivery of PTX [16]. The antitumor efficacy of LMWC-PTX 
was evaluated in murine melanoma cells and in xenografted human non-small cell lung carcinomas 
(NSCLC) after oral administration. The strong antitumor activity was attributable to the improved water 
solubility, prolonged retention in the gastrointestinal tract and the ability to bypass the efflux pump of the 
gastrointestinal, cells as well as the metabolism in the intestine and liver. Moreover, LMWC could open 
quickly and reversibly the tight junctions between human epithelial colorectal adenocarcinoma cells 
(Caco-2), a useful characteristic that can improve intestine absorption [71,82].  
Following an analogous approach, LMWC was also conjugated with DTX always through a  
succinate linker [17]. Cytotoxicity of LMWC-DTX conjugate was evaluated by MTT assay in human 
NSCLC-NCI-H358 and brain glioblastoma (U87MG) cell lines, showing similar effectiveness compared 
to the naked DTX. However, LMWC-DTX conjugate showed markedly enhanced (>200 times) water 
solubility compared to DTX alone. Moreover, following oral administration of LMWC-DTX in normal 
female BALB/c mice, blood half-life was increased by ~15-fold in comparison to the intravenously 
injected DTX. The in vivo antitumor efficacy was evaluated in nude mice bearing NCI-H358 and 
U87MG cells, respectively. The orally administered LMWC-DTX conjugate (10 mg DTX equivalent/kg) 
showed comparable antitumor efficacy to the same dose of the intravenously injected DTX for both  
NCI-H358 and U87MG models, but revealed much lower sub-acute toxicity as evaluated considering body 
weight loss and hematological toxicity in treated animals. 
Another use of CS involves the generation of theragnostic NPs. In this case NPs carry a diagnostic 
and a therapeutic molecule enabling diagnosis, therapy, and monitoring of therapeutic response at the 
same time [83]. The possibility of exerting “Therapeutic Drug Monitoring” allows in principle the 
individual adjustment of drug dosing. This implies that it may be possible to optimize the therapy for 
any specific individual reaching a “personalized treatment” which is expected to be more effective and 
less toxic than available therapeutic protocols. CS-based theragnostic NPs, produced as spherical 
structures with approximately 260 nm in diameter, were loaded with PTX and linked with the fluorescent 
dye Cy5.5 for imaging [18]. NPs were then administered intravenously to mouse xenografted with head 
and neck squamous cell carcinoma cell line (SCC7). The high stability in serum, deformability and rapid 
uptake by tumor cells, allowed the NPs to localize to the tumor mass with minor uptake by normal 
tissues. Fluorescence imaging, used to directly monitoring tumor size, revealed that NPs were 
approximately two times more effective in tumor size reduction compared to naked PTX. The authors 
claimed that the superior tumor specificity of NPs was responsible for an increased drug accumulation 
in the tumor tissue, eventually resulting in a more potent antitumor effect. It would be interesting to see 
whether these NPs may exert the same targeting properties also with different tumor types and/or a 
different experimental set up. Despite this, the advantage of using CS NPs remains obvious compared to 
the administration of naked PTX. 
More complex CS-based theragnostic NPs were generated with the possibility to monitor the drug 
release via Förster resonance energy transfer (FRET) [83]. A pH-responsive DOX-loaded NPs made of 
N-palmitoyl CS bearing a Cy5 fluorescent moiety (Cy5-CSNPs) were prepared [19]. The proper spatial 
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positioning of DOX and Cy5 allowed FRET to occur. After endocytosis in the fibrosarcoma cell line 
HT1080, it was possible to observe that DOX fluorescence in the cytosol was barely seen when NPs 
were present in the slightly acidic early endosomes. However, after NPs moving to more acidic organelle 
(late endosomes/lysosomes), an improved release of DOX into the cytosol was detected. Consequently, 
a progressive accumulation into the cell nuclei occurred, paralleled by a significant DOX induced 
cytotoxicity. Notably, due to its mechanisms of action, DOX can exert its effect only reaching the  
nuclear compartment. 
Photodynamic therapy (PDT) is a clinical treatment that employs photo-triggered chemical drugs as 
photosensitizers. To improve therapeutic efficacy and reduce the side effects in normal tissue, various 
nanoscale photosensitizer delivery systems have been developed [83]. As photosensitizers can generate 
both fluorescence and singlet oxygen upon laser irradiation, they can be used for both optical imaging 
and PDT at the same time [84]. In this regard, the hydrophobic photosensitizer chlorine e6 (Ce6) was 
loaded onto the hydrophobically-modified glycol CS NPs (average diameters of 300 to 350 nm) either 
by physical loading (HGCS-Ce6) or chemical conjugation (GCS-Ce6) [20]. Both HGCS-Ce6 and  
GCS-Ce6A displayed similar efficacy in vitro in the generation of singlet oxygen and a rapid cellular 
uptake in cultured SCC7. Compared to GCS-Ce6, HGC-Ce6 showed a burst of drug release in vitro, 
whereby 65% of physically loaded drugs were rapidly released from the particles within 6.5 h.  
However, following intravenous injection, HGCS-Ce6 did not accumulate efficiently in HT-29 human 
colon adenocarcinoma cells implanted in mice. In contrast, GCS-Ce6 had a prolonged circulation time 
and efficiently accumulated in the tumor, resulting in an excellent therapeutic effect. These findings 
suggest that the combined delivery of the two NP types may allow a fast delivery (HGC-Ce6) followed 
by slower release (GCS-Ce6), useful to maintain the pharmacological effects. The poor targeting ability 
of HGCS-Ce6 might be circumvented by adding targeting moieties on the NP themselves and/or 
including NPs in micro/macro delivery systems with targeting ability. 
CS has been also utilized in form of microparticles (MPs) to deliver drugs. In the study of  
Elgindy et al. [21] CS-MPs (particle size range of 0.63–1.13 mm) were undertaken for the oral prolonged 
release of flutamide (FLT-CS-MPs). FLT is a nonsteroidal antiandrogenic agent recommended for 
prostate cancer monotherapy. FLT and its more potent active metabolite 2-hydroxyflutamide, competitively 
block dihydrotestosterone binding at androgen receptors, forming inactive complexes that cannot 
translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and 
protein synthesis, resulting in the growth arrest of tumor cell. Since FLT has low bioavailability after 
oral formulations due to low water solubility [85], Elgindy et al. [21] developed a water soluble 
formulation for a prolonged release. Simple ionic gelation and emulsification-ionic gelation techniques 
were used to prepare FLT-CS-MPs. Different formulations of FLT-CS-MPs were prepared and their 
ability to release the drug was tested in vitro at low pH to simulate the gastric environment. In general, 
a fast initial drug release at pH 1.2 was observed for the first two hours followed by a prolonged drug 
release for the remaining 10 h of the experiment. Notably, depending on the FLT-CS-MPs formulation, 
variants on this release behavior were possible. Although promising, this study is very preliminary and, 
thus, further studies in more complex experimental models are necessary to fully clarifying its efficacy. 
In addition to the use in the form of NPs/MPs, CS has been also used as hydrogel for drug delivery. 
In this regard, there has been a great deal of interest in the use of hydrogels as chemotherapeutic drug 
delivery systems especially for oral administration. This is mainly due to the fact that the polymeric 
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chains of the hydrogel can closely interact with the saliva glycoproteins, causing a muco-adhesion 
phenomenon [86]. For example, Moura et al. [22] investigated in vitro CDDP release from  
thermo-sensitive CS hydrogels cross-linked with glycerol phosphate disodium salt (CS/GP) (narrow 
pore size distribution centered around a mode of about 60 µm) and CS hydrogels that were 
ionic/covalently co-cross-linked with genipin (CS/GP/GE) (broad pore size distributions with larger 
pores which modes are around 200 µm). Both hydrogels could be produced in situ under physiologic 
conditions. Notably, the two types of hydrogels behaved differently as drug delivery systems.  
The amount of drug released was of about 20% for CS/GP and about 60%–70% for the CS/GP/GE 
hydrogel during the experimental time. Despite these differences, from the qualitative point of view the 
release profiles were similar for both hydrogel types being characterized by an initial burst, which 
reached a plateau following about 2–3 h. These systems are very attractive for the treatment of oral cancers 
because of the muco-adhesive property of the hydrogel, which can guarantee a prolonged permanence of the 
drug in the mouth. Moreover, the release kinetic can provide a first burst of the drug, useful for an 
immediate antitumor effect; then the slow release step is appropriate to maintain the therapeutic effects. 
3.1.4. Hyaluronic Acid Based Delivery  
In mammalian organisms, native Hyaluronic acid (HA) represents one of the main constituents of the 
extracellular matrix (ECM). Moreover, HA can modulate cellular fate by receptor-mediated uptake.  
For example, HA can bind cluster determinant 44 (CD44), receptor for hyaluronate-mediated motility 
(RHAMM), HA receptor for endocytosis (HARE) and lymphatic vessel endothelial hyaluronan  
receptor-1 (LYVE-1), in all cases inducing specific cellular consequences. The above properties together 
with the intrinsic hydrophilicity, biocompatibility, biodegradability and non-immunogenicity, make of 
HA an excellent candidate for biomedical needs. 
DOX delivery by HA has been addressed in various works. Mesoporous silica (MPS) is a small 
nanomaterial known for its ability to host a large amount of drug and releasing it following changes in 
pH, temperature and by competitive binding [87,88]. The group of Chen [29] had chemically 
functionalized MPS surface with two chemicals (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) EDC 
and 3-(2-aminoethylamino) propyltrimethoxysilane NHS. The functionalization allows a homogeneous 
coating of MPS with HA, which results in high stability in physiological solution. Additionally, the HA 
coating of MPS allows the interaction with the receptor CD44, which is frequently over-expressed in 
tumors [89,90] and permits the complex internalization. Once in the cell, HA is digested by HA-specific 
enzymes leading to drug release into the cytosol from uncoated MPS. Based on this principle,  
Chen et al. [29] have found that MPS-HA loaded with DOX (MPS-HA-DOX) can decrease the viability 
of the human breast cancer cell line (MDA-MB-231) more effectively (15%) than DOX alone. 
Additionally, when administered to the non-tumor cell line NIH3T3, MPS-HA-DOX displayed 20% 
reduced unspecific toxicity compared to DOX alone. The authors explained this last feature with the 
reduced [91] expression of CD44 on NIH3T3, a fact which somehow protected the cells from particle 
binding and, thus, from DOX action.  
Another smart approach to deliver DOX by HA is exploiting pH sensitive modifications.  
An example of this strategy has been developed by Cai’s group [30]. Linking adipic acid hydrazide 
(ADH) to HA, the authors created a DOX (HA-DOX) conjugate. In this system the hydrazone bond 
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(between HA and DOX) is hydrolyzed faster at pH 5 than pH 7.4, thus allowing the release of DOX in 
an acidic environment, such as that found in tumors and in internalization vesicles. The PK and 
toxicology features of the conjugate were studied in an MDA-MB-468NL (human breast 
adenocarcinoma cell line) orthotopic xenograft rat model. Compared to free DOX, HA-DOX, 
administered by subcutaneous injection, showed a reduced pick in plasma concentration (about 1/4). 
From the toxicology perspective, free DOX but not HA-DOX treatment induced renal and cardiac 
dysfunction. Moreover, HA-DOX conjugates reduced tumor growth more efficiently than naked DOX, 
with an increased animal survival rate of 50% over a time of 24 weeks. Even though the system has been 
tested only in one in vivo model, the results suggest its possible use in HA over-expressing tumors, a 
property which however needs to be further proven. Additionally, to test the CD44 specificity of the system, 
it would have been interesting to verify the effectiveness in CD44 non-over-expressing tumor cells. 
The delivery of CDDP by HA based particles has been proposed by Xie et al. [31]. The authors tested 
a mono- and di-conjugate of CDDP and HA (HA-CDDP) in in vitro (A549 cell line, human lung 
adenocarcinoma epithelial cell line) and in vivo models (normal and xenografted rats) of lung cancer. 
The idea was to develop a local CDDP delivery to minimize the side effects that occur following CDDP 
intra veniously (i.v.) administration. Thus, the authors used the lung instillation route for HA-CDDP and 
compared the side effects with the classical i.v. administration of CDDP. Following lung instillation, 
HA-CDDP displayed better PK and reached higher concentrations in the lungs compared to  
i.v. administered naked CDDP. In particular, HA-CDDP reached 5.7- and 1.2-fold higher concentration 
than naked i.v. CDDP, 24 and 96 h after instillation, respectively. Notably, drug distribution to other 
tissues, such as brain, kidneys and liver was significantly more evident for naked i.v. CDDP compared 
to lung-instilled HA-CDDP. The more targeted localization of HA-CDDP resulted in reduced  
neuro- and nephron-toxic effects of HA-CDDP compared to CDDP. Whereas the investigation about the 
side effects are encouraging, future studies are required to examine the HA-CDDP therapeutic efficacy. 
A curious and recent application of HA-coupled PTX has been undertaken by Thomas et al. [32]. The 
authors, by linking 5β cholanic acid (CA) to HA, produced micelle able to encapsulate and solubilize 
PTX in a ratio of 10:1 w/w (HA-CA-PTX). The study has been carried out in vitro in the cancer cell line 
SCC7 and in in vivo models (xenografted mice). The SCC7 cell line (CD44 over-expressing) and 
NIH3T3 (CD44 low-expressing) cells as control, were preliminary tested for the uptake using particles 
loaded with fluorescent dyes (Flamma™-552) but not PTX. In SCC7 cells, the uptake was superior for 
the dye containing HA-CA particles compared to naked dye; notably, the uptake was significantly 
superior in the CD44 over-expressing SCC7 cells compared to the CD44 low-expressing NIH3T3 cells, 
thus proving the targeting ability. With regard to the antitumor effect, HA-CA-PTX at various 
concentrations (0.01–100 µg/mL range), resulted to be from 10% to 40% more effective than naked PTX 
in SSC7. Bio distribution experiments in vivo, carried out using Flamma™-774 labeled particles 
administered intravenously, demonstrated that HA-CA particles accumulate in the liver from where they 
are cleared one day after administration; in contrast, the tumor localization was maintained up to three 
days. The harvested organs confirmed the particle accumulation in the tumor and in liver and evidenced 
some accumulation in the kidney. The in vivo efficacy tests conducted with 5 mg/kg of PTX in HA-CA 
micelles intravenously injected, showed a significant inhibition of tumor growth compared to naked 
PTX. Notably, whereas the maximum effect of naked PTX was observed at day 4 after administration, 
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that of HA-CA-PTX occurred at day 8. This most likely reflects the different release kinetic, which may 
contribute to explain the improved therapeutic effect of HA-CA-PTX. 
As a last example of HA mediated drug delivery, we mention the work of Li et al. [33]. This very 
promising, though not fully tested study, is based on the use of polysaccharide-gold nano-cluster.  
The system is constituted by a supramolecular carrier of gold NPs (AuNPs) bearing adamantine moieties 
and β-cyclodextrin-modified HA (HA-CD). The strong affinity between the β-CD cavity and the 
adamantane moieties allows the system to be stable [92]. Additionally, the system permits drug release 
in mild acidic environments. Besides these features, the system has other favorable properties: good 
biocompatibility [93,94], convenient synthesis and facile size control [95], robust stability under most 
in vivo conditions [96], tunable surface features and dense loading functionalities for specific cell 
targeting [97,98]. A further advantage of this carrier is represented by the possibility to be loaded with 
different drugs. In this regard, the authors demonstrated satisfactory loading abilities for both 
hydrophobic and hydrophilic drugs. A preliminary application of HACD-AuNP coupled with DOX in 
MCF7 breast cancer cells (over-expressing CD44), showed a significant reduction in cell viability, 
comparable to that observed with naked DOX. Notably, in NIH3T3 (CD44 low expressing),  
no significant cytotoxic effects were observed, suggesting that the CD44 targeting is the key determinant 
for HACD-AuNP/DOX effects. To confirm the targeting ability, it would have been interesting to  
test whether MCF7 pretreatment by HA receptor binding molecules could have prevented  
HACD-AuNP/DOX toxic effects. Despite this, the work is potentially interesting and constitutes the 
basis for further in vivo tests.  
3.1.5. Dextran Based Delivery  
Dextran is considered a convenient delivery material due to its hydrophilic character, 
biocompatibility, biodegradability and easy chemical derivatization. 
A notable example of dextran-mediated delivery has been reported by the group of Luo [45].  
The authors developed a process to produce microcapsules fabricated via host-guest interaction between 
polyaldehyde dextran-graft-adamantane and carboxymethyl dextran-graft-β-cyclodextrin. This kind of 
interaction has strong stability and it is pH responsive, due to the presence of acidic-sensitive hydrazone 
bonds in polyaldehyde dextran-graft-adamantane. Adamantane was used as DOX linking site  
giving rise to a complex structure named carboxymethyl dextran-graft-β-cyclodextran/polyaldenhyde  
dextran-graft-adamantane and adamantine-modified DOX (CMD-g-β-CD/(PAD-g-AD and AD-DOX))4. 
The presence of pH responsive bonds was introduced to confer the ability to release the drug in the acidic 
cancer tissues. The pH responsiveness was tested first in vitro, where it was proved the particle stability 
and the capacity to release the drug in relation to acidification. In particular, at pH 5.5 about 80% of the 
loaded drug was released, while at physiological pH only 18% of the drug was delivered. The cytotoxic 
potential of the DOX loaded microcapsules was then tested in cultured HeLa cells (human cervical 
cancer cell line), at different pHs (7.4 and 5.5). At pH 7.4 only a small amount of DOX was absorbed and 
thus no important effect on cell viability was observed. Under acidic conditions, about 50% of loaded drug 
was released with a dramatic reduction in cell viability. The pH responsive property together with the 
excellent biocompatibility of the unloaded microcapsules, make this particle type very promising. Future 
tests in in vivo model are necessary to confirm the obtained results and to determine the PK and PD profiles. 
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Another interesting and innovative strategy has been proposed by Pramod et al. [46], who reported a 
dextran-based method able to deliver two different drugs from the same particle. Dextran  
nano-vesicles were generated with a dextran backbone bound to a hydrophobic pentadecyl phenol  
(DEX-PDP) group via an aliphatic ester linkage. As this bond can be hydrolyzed only by the lysosomial 
enzymes esterases, outside the cell environment it has a high stability. The vesicles can be loaded with 
hydrophilic molecules in the core and hydrophobic ones in the external layer. The amphiphilic nature 
allowed the concomitant loading with the water-soluble DOX and the hydrophobic irinotecan (CPT11), 
an inhibitor of topoisomerase I, of which cytotoxicity is related to double-strand DNA damage. 
According to FDA, CPT11 is recommended for the treatment of metastatic colorectal cancer. In the 
study of Pramod et al. [46], three different vesicle types were prepared: the first loaded with DOX, the 
second with CPT11 and the third one with both of them. Cytotoxicity and drug release were tested in 
MCF7 and DLD1 (human colon cancer) cell lines. In both cancer cell lines, the combined administration 
of DOX and CPT11 in a 4:1 ratio had the best effect in terms of cytotoxicity, killing 80% and 60% of 
MCF7 and DLD1 cells, respectively. Notably, the activity of the particles loaded with the two drugs was 
always superior to that of the same particles loaded with the two drugs separately. Tests in more complex 
in vivo models are now necessary to prove the effectiveness of the vesicles. Additionally, it may be 
interesting to test the effectiveness of vesicles loaded with different combinations of drugs.  
3.1.6. Pullulan Based Delivery 
Pullulan (P) represents another potential interesting polysaccharide due to its biocompatibility, water 
solubility, lack of immunogenicity, and to the presence of multiple hydroxyl groups that can be 
functionalized. Notably, P can target the hepatic cells due to the ability to interact with the  
asialo-glycoprotein receptor present on hepatocytes. A notable example of P use is represented by the 
work of Lee et al. [51], where PTX-incorporated NPs have been synthesized using P acetate. NPs were 
spherical with a size from 80 nm for empty NPs and up to more than 100 nm for those loaded with PTX. 
In vitro it was demonstrated that PTX was released with an initial burst that lasted up to day two, 
followed by a reduced release over one week. In RAW264.7 macrophage cells, NPs alone were nontoxic 
and when loaded by PTX, they exerted a significant antitumor activity in the HCT116 human colon 
carcinoma cells. However, NPs-PTX were less effective than naked PTX, probably due to the slowed 
release kinetic. This features, which was detrimental in cultured cells was, on the contrary, the probable 
reason for the success in vivo in HCT116 xenografted in athymic nude BALB/c mice. Following  
i.v. administration and starting from ten days after drug administration, NPs-PTX demonstrated a 
superior activity than naked PTX in reducing tumor growth. Notably, compared to naked PTX,  
NPs-PTX induced a reduced body weight loss, suggesting a reduced systemic toxicity. The authors 
proposed that, in addition to the slowed release kinetic, the success of the increased effectiveness and 
reduced side effect of NPs-PTX was also dependent on the EPR effect. Whereas being fully acceptable, 
this hypothesis could have been verified by studying the distribution into the tumor tissue of NPs-PTX 
compared to naked PTX. 
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3.1.7. Cellulose Based Delivery 
Cellulose, due to the biocompatibility and anti-microbial action, is one of the most promising 
materials for bio-applications. Although it is well known that cellulose is insoluble in many solvents and 
water, it can be chemically modified for improving its solubility. There are several commercial soluble 
derivatives of cellulose, such as hydroxypropyl methylcellulose (HPC), a non-ionic, thermoresponsive 
and biodegradable compound [99]. Metaxa and coworkers [39] used HPC conjugated to daunorubicin 
(DNR), a DOX analogue, via a glutathione-sensitive linker (N,N'-(disulfanediylbis(ethane-2,1-
diyl))bis(2-methylacrylamide) (DSBMA). In the presence of glutathione, the disulfide bridges of the 
polymeric layer are transformed into thiol groups, resulting in the slow release of DNR. As glutathione 
is highly concentrated in tumor cells [100], the system is in principle able to have a cancer cell specific 
effect. This feature may be further improved by the covalent modification of HPC with a folic acid 
receptor (FR) targeting moiety. Being that FR scarcely expressed in normal cells and over-expressed in 
a range of cancer cells, the system has an additional cancer cell targeting ability. The HPC-DNR particles 
were able to significantly reduce the vitality of the cancer cell line HeLa, over-expressing FR. In contrast, 
negligible effects were observed in the HEK293 (human embryonic kidney cell line), which express FR 
at low levels. Over a period of three days, HPC-DNR displayed reduced activity compared to naked 
DNR, probably due to the slow release kinetic. This hypothesis is supported by the observation that 
HPC-DNR could localize into HeLa cells. In particular, two hours after administration, the amount of 
HPC-DNR was higher compared to naked DNR, and negligible amounts were seen in the FR negative 
NIH3T3 cells. In vivo (mouse model), HPC-DNR displayed rapid clearance from circulation following 
intravenous administration and an uptake by the mononuclear phagocyte system. In this work,  
no evidence of the effects of glutathione on DNR release from HPC-DNR were presented; additionally, 
no evidence on the in vivo activity and specificity have been provided. Despite these aspects, the 
possibility to bind FR and release drug in high glutathione concentration, make the system interesting 
for further investigation.  
Another cellulose type, carboxymethylcellulose (CMC), can be used for drug delivery because of its 
hydrophilic nature. Plyduang et al. [40] explored this material to deliver tetrahydrocurcumin (THC). 
THC is the active metabolite of curcumin, a naturally occurring antioxidant, anti-inflammatory and 
anticancer agent [101]. However, due to its low water solubility, THC has only limited pharmacological 
activities. To overcome this drawback, Plyduang et al. [40] conjugated THC with CMC. In addition to 
being approved by FDA as a common excipient, CMC is inexpensive, has good compatibility to the skin 
and mucous membranes and presents suitable groups, which allow functionalization. The CMC 
derivative was conjugated with PABA (p-aminobenzoic acid) or PAH (aminohippuric acid)-diamine 
linkers, both of which can be cleaved by colonic bacteria. This property was chosen as the authors 
intended to prepare a colon-specific drug delivery material for the treatment of colonic cancer.  
To decrease side effects, the targeted drug delivery to the colon should not release the drug in the stomach 
and small intestine. After assessing the in vitro release of the conjugates (from 65% to 82% after 48 h), 
the analysis of cytotoxicity, revealed an increased toxicity in the human colon adenocarcinoma cell line 
HT-29 compared to the normal colon cell line CRL1790. This specificity, however, seemed to depend 
on the drug per se and not to any targeting ability of the delivery materials. The authors also showed that 
the incubation of the conjugates with gastric or small intestine homogenate resulted in a minor drug 
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release; however, in the presence of cecal content, drug release had a burst. The authors explained this 
behavior with the action of colonic bacteria, which could have triggered the cleavage of PABA/PAH 
linkers. Despite being potentially interesting, these data need to be confirmed in physiological model 
considering the delivery behavior in living animals. 
As mentioned before, the use of polysaccharides can be applied to integrate drug delivery and 
diagnostic/imaging in one system. These types of systems were, for example, investigated by  
Wu et al. [41]. The authors developed a class of multifunctional hybrid nanomaterials through the in situ 
immobilization of CdSe quantum dots (QDs) into the hydroxypropylcellulose-poly(acrylic acid)  
(HPC-PAA-CdSe) semi-interpenetrating (semi-IPN) nanogels. The fluorescent CdSe QDs is used for 
particles visualization; the HPC chains can provide rich-OH groups for sequestering CdSe ions into the 
gel network and stabilizing the in-situ formed CdSe QDs. Finally, the PAA chains are the pH sensitive 
portions that, depending on the pH, can induce reversible swelling/shrinking of the particles influencing 
drug delivery. Nanogels were successfully internalized into the mouse melanoma B16F10 cells as 
evaluated by fluorescence microscopy, giving no signs of morphological damage to the cells. The 
addition of the anticancer drug temozolomide (TMZ) into nanogel resulted in a significant reduction in 
B16F10 cell vitality compared to controls. Notably, nanogels did not alter the potency of TMZ as the 
drug either complexed in nanogels or in the naked form, had similar activity. TMZ is an oral anticancer 
agent approved for the treatment of newly diagnosed glioblastoma in combination with radiotherapy. 
The proposed nanogels may be useful to overcome some of the limitation of TMZ, such as the low 
solubility, the short half-life, and the considerable toxicity. In particular, TMZ toxicity may be reduced by 
adding to the nanogels cancer-cell targeting moieties. The developed nanogels are certainly promising for 
optimized drug delivery, but further in vivo studies are necessary to confirm their efficacy.  
3.1.8. Other Polysaccharide Based Delivery 
Other interesting, but thus far not yet deeply investigated, polysaccharides can be used as drug 
delivery materials. In this regard, a promising class is represented by sulfated polysaccharides.  
As most of them are negatively charged, they can bind positively charged molecules via electrostatic 
interaction. A recent study [80] considered the use of Halomonas maura, a halophile bacterial species, 
for its capability to produce huge amounts of sulfated exopolysaccharides particularly rich in sulfate 
residues. The numerous sulfate residues render this polysaccharide, named mauran (MR),  
an immune-modulating and anticancer agent itself. In the study, NPs composed of MR and CS were 
synthesized and filled with 5-FU (5-FU-MR). MR/CS NPs were synthesized by simple polyelectrolyte 
complexation of the anionic MR and the cationic CS. The obtained NPs, in the shape of spheres with a 
smooth surface, released 5-FU mainly via diffusion. No significant toxicity was observed in mouse 
connective tissue fibroblast cells (L929). Additionally, the authors could show that in MCF7 cells, the 
anti-proliferative capacity of 5-FU was enhanced following the release from NPs, compared to the naked 
drug. An explanation given for this observation was the increased 5-FU retention into the cells compared 
to the naked drug form. This feature together with the capacity to exert a sustained released of the drug 
(up to 10–12 days), indicate the interest for this kind of NPs, whose characterization should be further 
deepened to fully understand the effectiveness in drug release in vivo. 
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Another example of a not deeply studied polysaccharide is arabinogalactan (AG), a natural polymer 
extracted from Larix tree. The group of Pinhassi [81] created a smart system to ameliorate methotrexate 
(MTX) administration. MTX is a chemotherapeutic agent approved by FDA for the treatment of different 
cancers (breast cancer, acute lymphocytic leukemia). However, its administration causes different side 
effects. In the study of Pinhassi et al. [81], AG was conjugated with folic acid (FA), to allow the targeting 
to cancer cells which typically overexpress FA receptor. The drug loaded NPs displayed 6.3-fold 
increased cytotoxic activity in FR-over-expressing cells (AA8 Chinese hamster ovary cell line) compared 
to their FR-lacking counterparts. This interesting targeting ability will need to be confirmed in animal 
models; additionally it would be interesting to test whether the NPs could be conjugated with different 
targeting moieties to further improve the specificity of action. 
3.2. Polysaccharides for the Delivery of Nucleic Acid Based Drugs 
In addition to the clinically approved drugs, also other experimental molecules with potential 
therapeutic value can benefit from the polysaccharide-mediated delivery. Among the experimental 
molecules, we focussed on NABDs. These compounds, constituted by short sequences of either DNA or 
RNA, includes antisense oligonucleotides, decoys oligonucleotides, aptamers, triple helix forming 
oligonucleotides, DNAzymes, Ribozymes, small interfering RNAs (siRNAs) and micro interfering 
RNAs (miRNAs) [102–104]. As all NABDs are made of short nucleic acid molecules, they have 
comparable physical-chemical features. It follows that they display similar requirements in terms of the 
delivery material. Thus, whereas in this review we will focus on polysaccharide-based delivery systems 
for siRNAs/miRNAs, the same systems can be in principle effective also for the other class of NABDs. 
In the next section, we will present the general biological features of siRNA/miRNA (Section 3.2.1) 
together with the specific problems related to the release of these molecules (Section 3.2.2). Then, we will 
present (Sections 3.2.3–3.2.7) the employment of representative and widely studied polysaccharides for 
NABD delivery.  
3.2.1. Small and Micro Interfering RNA Molecules 
The RNA interference (RNAi) is a cellular process characterized by the degradation, in a sequence 
dependent fashion, of a target RNA by short double stranded RNAs (dsRNAs) [105]. miRNAs and 
siRNAs are the short dsRNAs able to trigger RNAi. While miRNAs are synthesized within the cell, 
siRNAs are commonly of exogenous origin deriving, for example, from viruses and transposons. With 
regard to the action mechanism, of the two RNA filaments constituting miRNA/siRNA, one (the  
so-called antisense strand) is up-taken by the cellular protein complex termed RISC (RNA-induced 
silencing complex), while the other (called sense strand) is discarded and does not take part to the 
silencing process. The antisense strand drives RISC to the target RNA that is bound via either a perfect 
or a partial complementarity in the case of siRNA or miRNA, respectively. In the case of miRNAs, the 
binding triggers the down-regulation of target gene expression most often by interfering with the 
translational machinery [106] and, in some cases, by inducing target RNA degradation by RISC.  
In contrast, siRNAs repress target gene expression only via RISC-mediated target RNA degradation. 
Due to the short length, miRNAs and siRNA can be easily chemically synthesized and used to target the 
Materials 2015, 8 2592 
 
 
mRNAs of genes causing disease. In this regard, there are several examples of the potential therapeutic 
value of miRNAs and siRNAs [107–113]. 
3.2.2. The Delivery Problems 
Whereas the therapeutic potential of miRNAs/siRNAs, which from now on will be collectively 
indicated as NABDs, is generally recognized, their practical use is limited. This is substantially due to 
the absence of optimal delivery systems able to efficiently protect and direct them to the target tissue.  
If administered systemically (vascular route) in the naked form (Figure 6), NABDs have to face with the 
obstacle of blood nucleases, which can rapidly trigger their degradation. Additionally, naked NABDs 
tend to be eliminated by the reticulo-endothelial system, by kidney filtration [114], and, in some cases, 
tend to activate the innate immunity [115,116]. The crossing of the vascular wall before reaching the 
diseased tissue, represents another obstacle to NABDs action. The efficiency of this process is strongly 
influenced by the size of the endothelium fenestration, a feature that can vary considerably among 
tissues. For example, the liver endothelium is highly fenestrated, thus favoring extravasation [117] and 
accumulation of NABDs in the liver. 
 
Figure 6. Biological obstacles in NABDs delivery. 
Once in the desired tissue NABDs have to overcome the problem of the cell membrane crossing. This 
step is unfavorable due to the negatively charged surface of cellular membranes, which tend to repulse 
the negatively charged phosphate groups present in NABDs. Additionally, the hydrophilic nature of 
NABDs disfavors the crossing of the hydrophobic layer of the cell membrane. In the cells, NABDs are 
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then susceptible to further degradation by cellular nucleases. In the cell, NABDs are also subjected to 
the cellular trafficking issue. This last aspect is relevant [118,119] as, following cellular uptake, NABDs 
can be sequestered into cytoplasmic vesicles named endosomes where they remain entrapped with no 
possibility to reach the target mRNA into the cell cytoplasm.  
Together all the above considerations clearly indicate that naked NABDs have no chance to exploit 
their therapeutic action. A strategy undertaken to overcome NABDs degradation is based on the 
introduction of chemical modification into their structure to make them resistant to nucleases-mediated 
degradation. A second possibility is represented by the complexation/binding to different synthetic 
materials. While the discussion of the NABDs chemical modification [111] goes beyond the scope of 
the present work, the strategies adopted to complex NABDs with synthetic materials represents the topic 
of this review. In particular, among the several materials available [111], we concentrate on the use of 
polysaccharides as delivery substances due to their wide use and versatility. The reported examples are 
described below and summarized in Table 3. 
Table 3. Polysaccharide-based delivery of NABDs. 
 System Structure Drug Disease 
In vitro  
Model 
In vivo  
Model 
Ref. 
Chitosan 
1 Bio-CS-g-PEI NPs siRNA Ovary cancer 
HeLa  
OVCAR-3 
– [23] 
2 
CS-TAT  
CS-nonaArg 
NPs 
siRNA anti 
luciferase/ 
survivin 
Brest cancer MCF7 Mouse [24,25] 
3 CS-γPGA NPs siRNA anti 
luciferase/GFP 
– HT1080 – [26,27] 
4 psi-Pgp-GCt NPs 
siRNA anti  
Pgp 
Brest cancer MCF7 Mouse [28] 
Hyaluronic Acid 
5 HA-Chol/2b NPs 
siRNA anti  
RFP 
– B16F10 – [34] 
6 PEG-HA-NP NPs 
siRNA anti  
Pgp siRNA anti 
GGCT 
Breast cancer MCF7 Mouse [35,36] 
7 CAP/dopa-HA NPs 
siRNA anti 
luciferase 
– HT29 Mouse [37] 
8 CAP-HA-DPA/Zn NPs 
siRNA anti 
luciferase 
– 
DU145  
143B HCT116 
Mouse  [38] 
Dextran 
9 Ac-DEX-spermine NPs 
siRNA anti 
luciferase 
– HeLa  – [47,48] 
10 DexS/pArg NPs 
siRNA anti  
GFP 
– HeLa – [49] 
11 DexS/pArg/HY NPs 
siRNA anti 
SPARC 
– Fibroblast – [50] 
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Table 3. Cont. 
 System Structure Drug Disease 
In vitro  
Model 
In vivo  
Model 
Ref. 
Pullulan 
12 P-PEI-FA NPs 
siRNA anti 
luciferase 
– HeLa – [52] 
13 Ps NPs siRNA – MDA-MB-231 – [53] 
Other 
14 CS/alginate hydrogel 
siRNA anti  
TNFα Colitis – Mouse [42] 
15 CS/alginate hydrogel 
siRNA anti  
CD98 
Colitis 
Colon-26 RAW 
264.7 
Mouse [43] 
16 PEI/alginate NPs 
siRNA anti 
VEGFR-3 
– EPCs – [44] 
17 PEG-Tf-CD NPs 
siRNA anti 
RRM2 
– – 
Mouse  
Non-human 
primate Clinical 
trial 
[120,121] 
3.2.3. Chitosan Based Delivery 
CS has been widely used as NABDs delivery agent mainly because it contains positively charged 
amino groups that permit the electrostatic interactions with the negatively charged NABDs.  
Darvishi et al. [23] have proposed the grafting of polyethyleneimine (PEI) on CS backbone. PEI is a 
synthetic polymer with a repeating unit of an amine group with two CH2 spacers. Due to the presence of 
protonable amino groups in every third position, PEI has a high cationic density under physiological pH, 
which allows the spontaneous formation of polyelectrolyte complexes with nucleic acids. In addition to 
PEI, Darvishi et al. [23] added biotin (Bio-CS-g-PEI) whose receptor tends to be over-expressed in 
cancer cells. Bio-CS-g-PEI resulted to be water-soluble at physiological pH and had optimal transfection 
efficiency for siRNA at the Bio-CS-g-PEI/siRNA weight ratio of 30. Moreover, Bio-CS-g-PEI/siRNA 
transfection efficiency was 44% and 22% higher than that of CS-g-PEI/siRNA and PEI/siRNA 
complexes, respectively, in the HeLa tumor cells. Worth noting is the fact that, in OVCAR-3 cells,  
a model of human ovary cancer cells over-expressing biotin receptors on the cell membrane,  
the transfection efficacy was 74% and 23% higher, compared to CS-g-PEI and PEI complexes, respectively. 
Together, these data strongly support the targeting potential of Bio-CS-g-PEI/siRNA in cancer cells  
over-expressing biotin receptors. Confirmatory experiments are now necessary in in vivo model. 
As an additional and interesting strategy to improve the efficiency of CS/siRNA transfection, cells 
penetrating peptides were used in combination with CS. In two different works it has been demonstrated 
that the grafting of TAT peptide [24] or nona-arginine peptide [25] ameliorated not only the quantity of 
internalized siRNA but also the silencing effect of siRNA compared to the siRNA delivered by 
unmodified CS. More in details, nona-arginine and TAT increased in MCF7 cells the uptake of 2.5 and 
13 folds, respectively, compared to the unmodified CS. Notably, both for nona-argine or TAT grafted 
CS, the cyto-compatibility was definitively superior to unmodified CS. Additionally, the siRNA 
mediated silencing effect was excellent reaching 75%. TAT-grafted CS also showed its effectiveness  
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in vivo, delivering a siRNA targeted against the mRNA of survivin, a protein known to inhibit cell 
apoptosis, thus favoring tumor cell survival. Following direct intra-tumor injection, TAT-CS-siRNA 
complexes were able to significantly reducing tumor growth in breast tumor-bearing mice in comparison 
to naked siRNA and saline treated mice. Interestingly, whereas mice treated by saline or naked siRNA 
developed lung metastasis, this was not the case for TAT-CS-siRNA treated animals [25], further 
showing the effectiveness of this delivery material. 
Despite being the above reported success in the use of CS as siRNA delivery material very 
encouraging, it should be kept into consideration the fact that the strong interaction CS-siRNA, may 
negatively affect the siRNA release into the cell. This seems to be particularly true for high molecular 
weight (MW) CS [122], even if high MW CS can efficiently protect siRNAs from degradation. On the 
other hand, low MW CS is not optimal in siRNA protection against degradation in the extracellular 
environment, but it can efficiently release the siRNA in the cell [123]. Together, these observations 
indicate that the balancing between CS protection and release properties of siRNAs needs to be 
optimized [124]. Additionally, this balancing may need to be optimized also in relation to the target cell. 
For example, CS with intermediate chain lengths mediated an efficient siRNA delivery in H1299 (human 
lung carcinoma cell line), in the MCF7 and in HUVEC (human umbilical vein endothelial) [125]. 
However, very poor delivery was observed by us in the human hepatic cancer cell line JHH6  
(Farra et al., unpublished results), suggesting a cell-dependent efficiency of uptake. 
With the purpose to improve CS-mediated delivery of siRNAs via the reduction of CS attraction 
towards siRNAs, Liao et al. conjugated to CS a negatively-charged poly(γ-glutamic acid), together with 
a γ-glutamyl unit at its N-terminal end (γPGA) [126] to form CS/γPGA complexes. As γPGA can be 
recognized by a membrane protein, γ-glutamyl transpeptidase (GGT), highly expressed in most 
mammalian cells, the entire CS/γPGA complexes were up taken by means of a receptor mediated 
endocytosis. Moreover, the authors showed that, using a double stranded DNA as a prototype of a nucleic 
acid molecule, the CS/DNA/γPGA complexes was gradually unpacked into the cell due to the 
electrostatic repulsion induced by the incorporated γPGA, which facilitated the intracellular release of 
DNA. This system was also used to deliver two disulfide bond-conjugated and PEGylated siRNAs  
(PEG, polyethylene glycol) directed against the mRNAs of luciferase and GFP (green fluorescence  
protein) [26]. To study the effects of the two siRNAs complexed with CS/γPGA (CS/siRNA/γPGA), the 
HT1080 cell line stably transfected with GFP/luciferase reporter gene plasmid was used. The authors 
could show that following endosomal escape, the negatively charged PGA of the CS/siRNA/γPGA was 
able to disrupt the strength of electrostatic interactions between the conjugated siRNAs and the 
protonated CS. This facilitated the release of the two siRNAs into the cytosol where the intracellular 
glutathione could reduce the disulfide bond of the conjugated siRNAs making them free and, thus, able 
to silence the respective target mRNA (GFP and luciferase). The maximum suppression of gene 
expressions (80%) was observed at day five after administration and persisted, although progressively 
reduced in extent, up to day eleven. Notably, whereas at day one CS/siRNA/γPGA could reduce gene 
expression down to 28%, the CS/siRNA complex only reached 50%, showing the relevance of  
γPGA [27]. Despite that these data are very interesting, the comparison with a LF mediated delivery 
could have better defined the efficacy of the system. 
An original CS-based delivery for siRNAs is the one proposed by Ji Young Yhee et al. [28].  
The authors used glycol chitosan (GC) polymers bearing thiol groups (GCt) (Figure 7).  
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Figure 7. CS-based delivery for siRNAs proposed by Ji Young Yhee et al. [28]. 
The siRNA of interest was also thiolated at the extremities, thus inducing the formation of a sort of 
poly-siRNA (psi). GCt and psi were then mixed and allowed to bind by electrostatic interactions and by 
the chemical conjugation via thiol groups. The siRNA sequence used was directed against the mRNA of 
P-glycoprotein (Pgp), which mediates the therapeutic drug efflux from cancer cells, thus inducing cancer 
cell multi drug resistance (MDR). The resulting NPs named psi-Pgp-GCt, were spherical with an average 
hydrodynamic diameter of approximately 270 nm. The NPs could protect siRNA molecules from the 
degradation exerted by cellular and extracellular nucleases. At high particle concentrations (59.4 μg/mL, 
400 nM of siRNA of irrelevant sequence), almost no reduction in the vitality of MCF7 was detected by 
MTT assay; in contrast, the siRNA of irrelevant sequence, released from lipofectamime (LF), displayed 
50% reduction in cell vitality. Additionally, the psi-Pgp-GCt NPs were able to enter the cytoplasm at 
neutral to acidic pH (pKa of chitosan= 5–7) and to escape the lysosomes due to the change of endosomal 
pH. With regard to the functional effect, psi-Pgp-GCt NPs (100 nM of siRNA against Pgp) induced 
significant Pgp suppression in MCF7 cells which, however, was somewhat inferior to that obtained by 
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the commercial available LF. Despite this, the reduction in Pgp levels reached by the produced NPs, was 
able to decrease the extrusion from the cells of the anti-cancer drug DOX. Thus, these data suggest that 
psi-Pgp-GCt may induce changes in drug sensitivity. This was proven by showing the reduced cell 
vitality following DOX administration in psi-Pgp-GCt transduced compared to non-transduced cells.  
In vivo, the bio-distribution of psi-Pgp-GCt delivered via the tail vein in MCF7 tumor-bearing mice, 
showed a predominant localization at the tumor site, which was about three times higher than in the 
control. Moreover, psi-Pgp-GCt co-treatment with DOX significantly enhanced the anti-cancer activity 
of DOX, as shown by the fact that the mean tumor volume of psi-Pgp-GCt + DOX group was 
significantly reduced compared to DOX treated animals. Thus, these data confirm, in vivo, the induction 
of drug sensitivity by psi-Pgp-GCt. Notably, the authors could also prove the significant reduction of 
DOX toxicity in animals treated by psi-Pgp-tGC NPs. 
3.2.4. Hyaluronic Acid Based Delivery 
The negative charge of HA does not allow an effective binding to the negatively charged NABDs.  
To overcome this limitation, HA has been used in combination with cationic polymers to form 
polyelectrolyte complexes by supramolecular self-assembly able to bind NABDs. In this regard, 
different molecules including PEI, Spermine [127], Poly L-Lysine [128], and other [1] have been tested. 
A notable example is represented by the work of Choi et al. [34]. The authors developed a siRNA 
delivery system based on HA-containing NPs with the HA backbone conjugated with cholesterol  
(HA-Chol NPs). HA-Chol NPs where generated with a variable number of cholesterol per 100 sugar 
residues (from 2.6 to 24). Then, the siRNA was combined with the 2b protein, a virus derived protein 
able to bind double stranded RNA (dsRNA). The author demonstrated that it was possible to encapsulate 
the 2b/siRNA complex into the HA-Chol NPs to form the HA-Chol/2b/siRNA complex. This particle 
showed a loading content of siRNA up to 11% w/w for NPs containing the higher amount of cholesterol. 
Using a siRNA directed against the red fluorescence protein (RFP), the authors showed that, in B16F10 
cells expressing RFP, HA-Chol/2b/siRNA particles efficiently reduced RFP mRNA and protein levels. 
Worth noting, the commercially available LF 2000 was significantly less effective than the  
HA-Chol/2b/siRNA complexes. This elegant delivery system needs now to be tested in more complex 
scenario in vivo, using therapeutic siRNAs to fully demonstrate its delivery power. 
HA can be also used as coating for positively charged NPs. The positive charge on the NP can interact 
with negatively charged serum protein, which can displace siRNA from the NP. This, in turn, results in 
the reduction of the amount of siRNA delivered to the target cells, and, to a certain extent, also in a 
possible off-targeting of the free siRNA with unpredictable effects in terms of toxicity. The coating with 
HA can minimize the siRNA displacement from the NPs thus improving cellular uptake, 
biocompatibility and colloidal stability. In this regard, an interesting example has recently been reported 
by Ran et al. [35]. The authors covalently linked HA to PEG molecules and used the resulting  
PEG-HA compound to coat liposome-siRNA NPs. Whereas liposome are commonly used as siRNA 
delivery molecules, they are not optimal for systemic delivery of siRNA and, thus, need to be conjugated 
with “smart molecules”. The addition of PEG can efficiently shield the positive charge of liposome, thus 
reducing the siRNA displacement by negatively charged serum protein, from the NP (PEG-NP). 
However, PEG tend to reduce the cellular uptake and compromise endosome escape. HA can contribute 
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to overcome these problems, as shown by Ran et al. [35] with the generation of liposome NPs coated by 
PEG-HA (PEG-HA-NP). PEG-HA-NP, with an average diameter of 190 nm and a negative surface 
charge, were stable in fetal bovine serum up to 24 h. Compared to NP, PEG-HA-NP carrying a siRNA 
directed against the mRNA of the P-glycoprotein, resulted in a more efficient down regulation of target 
mRNA in MCF7 cells. Because of the good stability in serum, the systemic administration of  
PEG-HA-NP could efficiently deliver the siRNA in tumor bearing mice reaching a 34% P-glycoprotein 
down regulation. In contrast, no activity was detected for siRNA delivered from either NP or HA-NP. 
As P-glycoprotein is involved in the efflux of drugs outside the cells, in so preventing drug accumulation 
into the cell its down regulation by the PEG-HA-NP delivered siRNA can contribute to reduce the 
problem of drug resistance in breast cancer cells. To further confirm the reliability of the PEG-HA-NP 
approach, in a different work by the same author [36], this system was successfully tested in MCF7 cells 
for the delivery of another siRNA targeted against γ-glutamylcyclotransferase (GGCT), a protein 
upregulated in various types of cancer cells. Since HA can selectively bind CD44, the use of  
PEG-HA-NP may be in principle extended to the targeting of the many different CD44 over-expressing 
tumor cells. However, the extent of the increased efficacy of PEG-HA-NP in CD44 over-expressing 
compared to under expressing cells remains unclear since the authors did not specifically address this 
aspect in their work.  
HA has been combined with calcium phosphate (CAP), a natural inorganic material that can be found 
in bone and teeth. This material has been frequently used as gene delivery agent due to its 
biocompatibility, biodegradability, and ability to encapsulate negatively charged genetic material via the 
chelation of calcium ions during the process of calcium-phosphate crystals formation. The lack of 
delivery specificity and the uncontrollable growth of CAP crystals in a physiological solution has, 
however, limited its use as gene delivery system in vivo. Very recently, the conjugation of CAP with  
3,4-dihydroxy-L-phenylalanine (DOPA), an unusual amino acid found in adherent threads of marine 
mussels, has been proposed as a novel device for the targeted siRNA delivery to tumors [37] in 
conjunction with HA. HA-DOPA was first synthesized and then used to stabilize the CAP/siRNA NPs, 
upon absorption on their surfaces. Due to the adhesive properties, the DOPA molecules have the role to 
bind to the surface of CAP particles while the hydrophilic HA backbone exerts protective functions and 
serves as a targeting moiety for CD44+ cancer cells. At the weight ratio DOPA-HA/siRNA of 60, the 
siRNA incorporation efficiency was about 84%; additionally, no significant cytotoxicity was observed 
as evaluated by MTT test. CAP/DOPA-HA containing an anti-luciferase siRNA (DOPA-HA to siRNA 
weight ratio of 60), reached in CD44+ human colon carcinoma cells (HT29-luc) over-expressing 
luciferase, 50% reduction of target gene expression. In addition to showing that the uptake mechanism 
of CAP/siRNA/ DOPA-HA was regulated by receptor-mediated endocytosis, the authors also 
demonstrated that the acidic endosome pH promotes CAP dissolution determining an increase in the 
concentration of calcium and phosphate ions. This, in turn, induces the swelling and disruption of the 
endosomal membrane due to increased internal osmotic pressure with the consequent siRNA release.  
In animals bearing HT-29-luc tumor xenografts, CAP/siRNA/DOPA-HA administered via the tail vein, 
accumulated predominantly in the tumor mass and, in part, also in the liver. This last phenomenon may 
be attributed to the presence of the HARE receptor in hepatocytes; however, no signs of hepatic toxicity 
were detected following the histological evaluation of the liver and the evaluation of the liver function tests. 
In our opinion, this observation needs further careful investigations. Notably, CAP/siRNA/DOPA-HA  
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was able to significantly suppressing the expression of the target gene (luciferase) after a single dose  
(0.6 mg/kg) administered via the tail vein.  
Another recent and interesting work based on the use of CAP and HA has been reported by  
Choi et al. [38] (Figure 8). The siRNA NP is composed by four major components: (i) a hydrophilic HA 
shell; (ii) a hydrophobic 5β-cholanic acid (CA) inner core; (iii) a phosphate receptor  
Zn(II)-dipicolylamine (DPA/Zn); (iv) a calcium phosphate layer (CAP). The HA shell confers the ability 
of NPs to bind CD44 positive tumor cells, CA offers the possibility to load into NPs hydrophobic drugs 
and DPA/Zn allows the binding to siRNA. In particular, DPA/Zn binds siRNAs via specific interactions 
between coordinated zinc ions of DPA and anionic phosphates of the RNA. Due to the significantly high 
phosphate concentration in the bloodstream, which can perturb the siRNAs-DPA/Zn binding, the author 
added CAP layers onto HA-DPA/Zn/RNA by in situ mineralization of sequentially added calcium and 
phosphate ions. In this way, the CAP layer can protect the DPA/Zn/RNA interaction in the biological 
environment. Additionally, as above discussed, at the low pH of endosome, the CAP is dissolved, favoring 
the endosome escape of DPA/Zn/RNA. Notably, the phosphate ions released from CAP competitively 
bind with DPA/Zn receptors triggering the HA-siRNA release. Subsequently, the HA backbone can be 
degraded by the enzyme hyaluronidase, abundant within tumor cells, eventually resulting in the release of 
the free siRNA. Worth note is the fact that this kind of NPs can allocate, in addition to siRNAs or other 
NABDs, also hydrophobic drugs due to the presence of CA. Thus, this NPs can be used to exert synergistic 
therapies mediated by siRNAs and hydrophobic drugs, such as those commonly used in cancer 
chemotherapy. Using red fluorescent labeled siRNA (Cy3-siRNA) Choi et al. [38] could detect in the 
prostate tumor cells DU145 and 143B, a strong fluorescence signal, which was about three times more 
intense than that obtained delivering the siRNA by liposomes. Moreover, releasing a siRNA directed 
against the luciferase gene in 143B tumor cell line over-expressing luciferase, the authors observed thirty 
times more activity of the NP-siRNA complexes compared to the liposome-mediated delivery of siRNA. 
In a HCT116 xenograft mouse model, NPs intravenously injected were able to dramatically reduce the 
expression of the target gene (Luciferase) over-expressed by the HCT116 tumor cell line. Interestingly, 
it was also demonstrated the feasibility of miRNA delivery by the prepared NPs. Finally, the authors 
also provided evidences of the possibility to co-deliver the anticancer drug PTX and siRNA to the 
HCT116 cancer cells. Notably, in an evolution of the above NPs, the authors [129] showed the feasibility 
to convert the functional group of Zn-DPA into other groups including a carboxylic or thiol group; 
moreover, the DPA analog can be covalently attached to different formulations suitable to generate 
multifunctional delivery materials via standard bio-conjugation techniques. Together, these data fully 
underline the great versatility of the proposed system.  
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Figure 8. HA-based delivery for siRNAs proposed by Choi et al. [38]. 
3.2.5. Dextran Based Delivery 
Thus far, several types of dextran-based NPs have been generated for NABD delivery. From the first 
attempt where dextran alone was bound via electrostatic interaction to NABDs, more complex solutions 
have been proposed. For example, Naeye et al. decorated the dextran/NABDs NPs with a hydrophilic 
PEG shell for the intravenous delivery route [130,131]. Whereas PEGylation did not prevent the partial 
dissociation of NABDs in human plasma, it was able to prevent NPs aggregation and the lysis of red 
blood cell. However, a clear charge dependent interaction with platelets and leukocytes was observed. 
On one hand, these results suggest the positive NPs features able to prevent a significant interaction with 
red blood cells; on the other hand, they indicate that further improvements aimed at the reduction of 
platelet interaction are necessary. 
Another example of dextran NPs modification consisted in the conjugation of an acetal-modified 
dextran (Ac-DEX) with spermine as NABD delivery material [47]. The cationic nature of spermine 
improved the NPs complexation with the negatively charged siRNA and facilitated the cell membrane 
binding. Additionally, the Ac-DEX-spermine NPs resulted to be efficiently released from endosome, 
thus allowing the siRNA distribution with the cell cytoplasm [48]. This in turn resulted in an efficient 
silencing of the expression of the luciferase gene in HeLa cells expressing luciferase. 
Very recently, dextran was used to encapsulate NPs containing NABD and PEI [49]. In particular, the 
authors encapsulated NABD/PEI with multiple layers of dextran sulfate (DexS) and poly-L-arginine 
(pArg). The idea below this approach is that the DexS/pArg layers can protect the NABD in the 
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extracellular environment and prevent the known toxic effects of PEI. Once in the cellular environment, 
the DexS/pArg layers are progressively degraded, allowing PEI to mediate the known endosomal escape 
effect, thus favoring NABD translocation to the cytosol. As a cellular model it was used the HeLa cell 
line expressing the GFP against which the effect of an anti-GFP siRNA was tested. DexS/pArg capsule 
increased siRNA activity by about two to three times compared to the non-encapsulated PEI/siRNA. 
Notably, it was also shown that the minimal concentration of siRNA able to exert a visible effect was of 
2.6 nM; in contrast, for the commonly available transfection reagents a concentration of about 100 nM 
was necessary. This data strongly support the potency of the system proposed that, in addition, displayed 
negligible cytotoxicity.  
In a similar approach to that above reported, DexS and pArg were recently used to coat a core of 
hydroxyapatite (HY) particles [50]. The technique used is the layer-by-layer (LbL) self-assembly, a 
method based on the electrostatic interactions between positively (pArg) and negatively (DexS) charged 
polymers. A siRNA was inserted within the two most external pArg layers with an efficiency of about 
97%. The resulting NPs yielded a size of 350 nm with a superficial charge of +43 mV. Initial studies 
performed using a fluorescently labeled siRNA indicated an efficient uptake into fibroblast with a clear 
cytoplasmic but not nuclear localization. The nuclear exclusion was explained with the size of the NPs, 
which was probably too big (350 nm) to enter the nucleus. NPs displayed a good endosome escape and 
a subsequent defoliation of the external pArg layers that allowed the siRNA homogeneous release into 
the cytoplasm. For the functional studies, a siRNA target against the secreted protein, acidic and rich in 
cysteine (SPARC) was chosen. SPARC is a calcium-binding matricellular protein that modulates 
cell/extracellular matrix and is involved in the generation of pathological tissue scarring and fibrosis. 
Thus, SPARC targeting may be a useful approach to modulate pathological fibrosis. The authors could 
show a significant reduction in the protein and mRNA levels of SPARC in fibroblasts; however, as it 
was not introduced a control containing a scrambled siRNA embedded into NPs, it is hard to evaluate 
the real effectiveness of the proposed system.  
3.2.6. Pullulan Based Delivery 
Due to its non-ionic nature, P functionalization with positive groups is necessary to allow the 
complexation with NABDs. P use as NABD delivery material has been recently undertaken by  
Wang et al. [52]. In this case, a low MW branched PEI (1000 Da) was grafted onto the backbone of P 
with succinic acid as a spacer; then PEI was conjugated with a peptide (FA) able to bind FR to generate 
the complex P-PEI-FA. FR is a tumor marker over-expressed on the cellular membrane of different 
malignant cells. P-PEI-FA showed significantly reduced toxicity compared to PEI in the HeLa cell line. 
P-PEI-FA complexation with nucleic acid molecules confirmed the modest toxicity in different cell 
tumor lines (Human hepatocellular carcinoma HepG2, HeLa and MCF7). The only exception occurred 
for the African green monkey kidney cell (COS-7) was, at the highest weight ratio tested, 50% reduction 
of cell viability was observed, thus suggesting a species-specific toxicity. In the HeLa cell line expressing 
the luciferase gene, P-PEI-FA complexed with an anti-luciferase siRNA, reduced luciferase expression 
by 82%, showing slightly higher gene silencing efficiency compared to P-PEI-siRNA (71%) and LF 
2000-siRNA (76%). Notably, P-PEI-FA displayed also a targeting ability as it was highly effective in 
transducing the GFP expressing plasmid into the FR expressing HeLa cells but not in the FR  
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non-expressing HepG2 cells. Together, these data suggest the feasibility of the use of P as NABD 
delivery material; tests in in vivo models will better define the efficacy of the proposed system. 
In another recent work, it has been investigated the effects of serum on the transduction capability of 
NPs containing P chemically modified by spermine (pullulan-spermine, Ps) [53]. Serum is known to 
affect the transduction efficacy as it tends to be adsorbed by cationic molecules thus inducing the 
displacement of NABDs from NPs. Zhang et al. improved our knowledge about the effects of serum 
demonstrating that serum can significantly influence the NPs size and, thus, the transfection efficacy.  
In particular, the authors showed that low serum concentration (1.25% and 2.5%) in culture medium 
results in large particles of Ps-siRNA, while high serum concentration (10% and 40%) leads to small 
particles of Ps-siRNA. Compared to the small particles, large particles contain more amines eliciting a 
stronger proton sponge effect, which determines a more effective lysosomal escape of siRNA, and, thus, 
an improved siRNA biological effect. Notably, the large particles at the serum concentration of 1.25% 
display a transfection efficacy about seven times higher than that of the commercially available LF in 
the cancer cell line MDA-MB-231. Despite the higher transfection rate, large particles are more toxic 
than small ones. These interesting results prove the usefulness of P as NABDs delivery material and 
indicate the necessity to optimize NABDs also release in relation to serum-dependent effects. 
3.2.7. Other Polysaccharide Based Delivery 
Whereas the above-described polysaccharides have been often used as NABD delivery materials, 
other polysaccharides exist with a less frequent use. Among these, an interesting polysaccharide is 
represented by alginate. Due to its ability to form hydrogels, alginate has been mostly used for the 
controlled release of small molecule and protein. In this regard, a recent example is represented by the 
work of Laroui et al. [42]. Fab'-bearing TNFα-siRNA-loaded NPs were encapsulated into a matrix of 
CS/alginate and administered orally to mouse with induced colitis. Being colitis an inflammatory 
disease, the targeting of a pro-inflammatory cytokine, such as TNF-α, is considered beneficial to relieve 
inflammation. Moreover, the addition on the NPs of the Fab' portion of the F4/80 antibody, allows the 
targeting of macrophages, inflammatory cells sustaining colitis. The administration into the mouse colon 
of TNFα-siRNA-loaded NPs covered by Fab' was significantly more effective than the uncovered NPs 
in lessening colitis as shown by the attenuation of all parameters of colonic inflammation. Moreover, 
grafting Fab' onto the NPs improved the kinetics of endocytosis, as well as the macrophage-targeting 
ability. The use of alginates as releasing hydrogel was also considered in a similar recent work [43]. NPs 
were functionalized with molecules able to target CD98, an antigen whose over-expression on the 
surface of colonic epithelial cells and macrophages promotes the development and progression of colitis. 
NPs, loaded with an anti CD98 siRNA, were tested in vitro and in vivo embedded into CS and alginate 
hydrogel. In vitro, the NPs significantly reduced the levels of CD98 in the cell lines Colon-26 cells and 
RAW 264.7 macrophages, along with the reduction of inflammatory cytokines (TNFα, interleukin-6, 
and interleukin-12). Notably, administered orally to mouse with induced colitis, NPs also significantly 
reduced the severity of colitis. Collectively, these results show the relevant role of alginates hydrogel in 
delivering NABD loaded NPs. 
Whereas alginates have been mainly considered as delivery hydrogel, only a limited number of works 
have used this molecule to prepare nanostructure for NABD release. In the past, alginate has been 
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employed to reduce PEI cytotoxicity and Patnaik et al. showed successful siRNA transfection in various 
cell lines in vitro with PEI-alginate NPs containing PEI of different MW (25 kDa or 750 kDa) [132]. 
Very recently, NPs containing 25 kDa branched PEI and alginate were prepared and loaded with a siRNA 
targeting the mRNA of VEGFR-3 (vascular endothelial growth factor receptor-3) [44]. The  
VEGF-C/VEGFR-3 signaling pathway is involved in endothelial progenitor cells (EPCs) differentiation 
towards lymphoangiogenic cells; moreover, lymphangiogenesis is implicated in lymphatic metastasis of 
tumor cells. Thus, targeting VEGF-C/VEGFR-3 may be a useful approach to down regulate tumor 
lymphangiogenesis and lymphatic metastasis. NPs, with an average size and surface charge of 139.1 nm 
and 7.56 mV, respectively, were effective in reducing VEGFR-3 in purified EPCs. A limitation of these 
data is represented by the fact that only a semi-quantitative test was used to reveal the mRNA level of 
the siRNA target. Despite this fact, the authors could show the reduction in EPCs differentiation into 
lymphatic endothelial cells, together with a reduced attitude to proliferate and migrate. Confirmation in 
in vivo model is now necessary to deeply understanding the power of these alginate-based NPs. 
Finally, among other polysaccharide able to release NABD, cyclodextrin has to be mentioned. CDs 
are naturally occurring cyclic oligosaccharides, consisting of α-1,4 linked D-glucopyranose units. They 
are characterized by an amphiphilic topology as they form structures hydrophilic on the exterior part and 
hydrophobic in the inner part. This configuration allows CD to carry hydrophobic molecules inside and 
outside hydrophilic compounds. CD are also indicated as drug delivery materials as they improve cellular 
delivery, resistance to endonucleases and can reduce immunogenicity. In NABD delivery, CD can be 
used as either backbone polymer or as derivative grafted on other polymers. Whereas a detailed 
description of CD as NABD delivery has been given recently elsewhere [1], here we will just concentrate 
on some notable examples. With regard to the use of CD as backbone polymer, it should be mentioned 
the works of Davis’ group [133–135]. In this case, PEG and transferrin (Tf) were linked to the CD 
backbone. Tf was introduced to allow the targeting of cancer cells, which often overexpress the Tf 
receptor. The resulting PEG-Tf modified CD complexes, loaded with siRNA targeting the ribonucleotide 
reductase subunit M2 (RRM2), showed significant tumor growth inhibition in murine models [120]. 
Moreover, dose-escalating studies in non-human primates demonstrated that PEG-Tf modified CD 
complexes were well tolerated. This delivery approach named RONDEL™ (“RNAi/Oligonucleotide 
Nanoparticle Delivery”, Calando Pharmaceuticals) was tested in the first in-human phase I clinical trial 
administered to patients with solid cancer refractory to standard therapies [121]. NPs were detected in 
post-treatment tumor biopsy sections together with a significant down-regulation of RRM2. 
With regard to the use of CD as derivative molecule grafted on other polymers, we believe the works 
of Kulkarni et al. [136,137] represent relevant examples. CD was used as derivatization molecule for a 
neutral polymer, i.e., poly(vinyl alcohol) (PVA) polymer bearing PEG and cholesteryl (Chol) or 
adamantane (Ad) modified grafts. The resulting CD-Chol/Ad-PVA-PEG NPs were able to form 
complexes with siRNA via electrostatic interactions. Worth note, the siRNA delivered by this NPs had 
comparable efficacy as the same siRNA released from PEI or LF 2000, while being far less toxic. 
4. Conclusions 
A significant limitation in the administration of conventional anticancer drugs is related to their high 
toxicity mostly dependent on the impossibility to discriminate between cancer and normal cells. Toxicity 
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may also depend on the presence, in the pharmaceutical preparations, of molecules necessary to improve 
the poor solubility in water of many anticancer drugs. With regard to NABDs, an emerging class of drug 
with potential therapeutic value, despite evidence of their effectiveness, the practical use is limited. This 
mainly depends on the lack of materials able to overcome the delivery problems such as the fast 
degradation in biological fluids, the difficulties to cross cell membrane and the sequestration into cellular 
lysosomes. Thus, both for conventional anti-cancer drugs and NABDs, the development of optimal 
delivery materials may radically improve their therapeutic effectiveness. Additionally, appropriate 
delivery materials may allow the combined administration of conventional drugs and NABDs, possibly 
potentiating their therapeutic effects. 
Among the several delivery materials studied thus far, polysaccharides represent very attractive 
molecules as they can be obtained in a reproducible way from natural sources, can undergo a wide range 
of chemical and enzymatic reactions, are biocompatible, biodegradable and have low immunogenic 
features. Together, these characteristics make polysaccharides excellent candidates for the realization of 
“smart” delivery systems capable to release, at the appropriate time and site of action the entrapped 
drugs. However, the development of such delivery systems is not an easy task due to the several aspects 
to be considered. First, it is important to optimize the polysaccharide-drug interaction,  
a variable that depends on the physical–chemical properties of the polysaccharide and of the drug. 
Second, it is necessary to optimize pharmacokinetics and pharmacodynamics through a careful 
evaluation of the ADME phenomenon. Third, it is necessary to confer a targeting ability to the 
polysaccharide carrier to limit the off targeting to healthy tissue. Finally, for the applications considering 
drug delivery from a gel, it is important to study the release mechanisms of the drug from the gels. 
Together, these considerations clearly indicate that only a multidisciplinary approach can successfully 
afford the task of the selection of the optimal delivery materials for the drug and application of interest. 
Whereas an ideal delivery system is not yet available, the examples reported in the present review 
indicate that many interesting options, based on the use of polysaccharide, are emerging. Thus, whereas 
additional research is required, the promising results obtained thus far fully justify further efforts in terms 
of both economic support and investigations in the field. 
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ATP binding cassette transporter B1 ABCB1 
Absorption, Distribution, Metabolism and Elimination ADME 
Arabinogalactan AG 
Biotin Bio 
Calcium phosphate CAP 
Cluster determinant 44 CD44 
Cisplatin CDDP 
Cyclodextrins  CDs 
Carboxymethylcellulose CMC 
Irinotecan CPT-11 
Chitosan CS 
Daunorubicin DNR 
Doxorubicin DOX 
Double stranded RNAs dsRNAs 
Docetaxel DTX 
Extracellular matrix ECM 
Endothelial progenitor cells EPCs 
Enhanced permeability and retention effect EPR 
Folic acid FA 
5-fluorouracil 5-FU 
Flutamide FLT 
Folic acid receptor FR 
Förster resonance energy transfer FRET 
Glycosaminoglycans GAGs 
Green fluorescence protein GFP 
γ-glutamylcyclotransferase GGCT 
Hyaluronic acid HA 
HA receptor for endocytosis HARE 
Hydroxypropyl methylcellulose HPC 
Hydroxyapatite HY 
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Interpenetrated polymeric networks IPN 
Lipofectamine LF 
Low molecular weight chitosan LMWC 
Lymphatic vessel endothelial hyaluronan receptor-1 LYVE-1 
Multi drug resistance MDR 
micro interfering RNAs miRNAs 
Mesoporous silica MPS 
Microparticles MPs 
Mauran MR 
Methotrexate MTX 
Molecular weight MW 
Nucleic acid based drugs NABDs 
Nanoparticles NPs 
Pullulan P 
Pullulan-spermine Ps 
p-aminobenzoic acid PABA 
Aminohippuric acid-diamine PAH 
Pharmacodynamics PD 
Photodynamic therapy PDT 
Polyethylene glycol PEG 
Polyethyleneimine PEI 
P-glycoprotein Pgp 
Pharmacokinetics PK 
Paclitaxel PTX 
Red fluorescence protein RFP 
Receptor for hyaluronate-mediated motility RHAMM 
RNA-induced silencing complexes RISC 
RNA interference RNAi 
Ribonucleotide reductase subunit M2 RRM2 
small interfering RNAs siRNAs 
Acidic and rich in cysteine SPARC 
Transferrin Tf 
Tetrahydrocurcumin THC 
Temozolomide TMZ 
Vascular endothelial growth factor receptor-3 VEGFR-3 
Cell lines 
brain glioblastoma (human) U87MG 
breast cancer cell line (human) MDA-MB-468NL 
breast cancer cell line (human) MDA-MB-231 
breast cancer cells (human) MCF7 
cervical cancer cell line (human) HeLa 
colon adenocarcinoma (human) HT29 
colon cancer (human)  DLD1 
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colon carcinoma cells (human) HCT116 
colon cell line (human) CRL1790 
colon cells (human) Colon-26 
colorectal adenocarcinoma cells (human) Caco-2 
connective tissue fibroblast cells (mouse) L929 
fibroblast (murine) NIH3T3 
fibrosarcoma cell line (human) HT1080 
head and neck squamous cell carcinoma (human) SCC7 
hepatic cancer cell line (human) JHH6 
hepatocellular carcinoma cell (human) HepG2 
kidney cell (African green monkey) COS-7 
lung adenocarcinoma epithelial cell line (human) A549 
lung carcinoma cell line (human) H1299 
macrophage cells (murine) RAW264.7 
melanoma cell line (mouse) B16F10 
non-small-cell lung carcinoma (human) NSCLC-NCIH358 
ovary cancer cells (human) OVCAR-3 
ovary cell line (chinese hamster) AA8 
prostate tumor cells (human)  DU145 
prostate tumor cells (human) 143B 
umbilical vein endothelial (human) HUVEC 
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